Positions

Overview

  • Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS is Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology, and Director of the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine at the University of Alabama at Birmingham (UAB).

    Dr. Oparil is a cardiologist with a special interest in the fundamental mechanisms of cardiovascular disease and in applying this information to the development of novel treatments. She was involved in early research of the fundamental mechanisms of vascular disease and has made many groundbreaking observations that have greatly impacted clinical medicine.

    Dr. Oparil served as president of the American Heart Association (AHA), the American Society of Hypertension (ASH), and was the first female president of the American Federation for Clinical Research (AFCR). She has held important advisory positions with the NIH, including task forces, expert panels, peer-review and guidelines committees. She has received numerous lectureships and distinguished awards for her contributions to academic medicine. She serves on editorial boards of a variety of medical journals and is member of numerous prestigious organizations in academic medicine.

    Dr. Oparil plays an essential role in the development of cardiovascular research training at UAB. She has mentored numerous students and fellows, many of whom now lead academic programs at prestigious institutions throughout the country. Dr. Oparil is a remarkable leader in hypertension research and continues to break new ground in cardiovascular research
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.Clinical Journal of the American Society of Nephrology.  13:1816-1824. 2018
    2018 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension.Blood Pressure.  27:313. 2018
    2018 Effect of sleeve gastrectomy on hypertension.Journal of the American Society of Hypertension.  12:e19-e25. 2018
    2018 Number of Measurements Needed to Obtain a Reliable Estimate of Home Blood Pressure: Results From the Improving the Detection of Hypertension Study.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  7:e008658. 2018
    2018 Obesity and Pulmonary Hypertension.Current Hypertension Reports.  20:99. 2018
    2018 Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults.Journal of the American Medical Association.  320:1338-1348. 2018
    2018 Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study.Blood Pressure.  27:247-248. 2018
    2018 Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  7:e009326. 2018
    2018 Take a blood pressure pill or benefit from renal denervation?European Heart Journal.  39:3010-3012. 2018
    2018 Novel Medical Treatments for Hypertension and Related Comorbidities.Current Hypertension Reports.  20:90. 2018
    2018 Revisiting ASCOT 16 years later.Lancet.  392:1092-1094. 2018
    2018 Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients.Circulation Research.  123:531-534. 2018
    2018 Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.Hypertension.  72:343-349. 2018
    2018 Final Farewell to Alberto Zanchetti MD.European Heart Journal.  39:2616-2617. 2018
    2018 Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk.Current Hypertension Reports.  20:77. 2018
    2018 Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting.Hypertension.  72:3-9. 2018
    2018 Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure.Blood Pressure.  27:185-187. 2018
    2018 Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes.European Journal of Nuclear Medicine.  45:1998-2008. 2018
    2018 Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).Hypertension.  71:1064-1074. 2018
    2018 In memoriam: Alberto Zanchetti.Blood Pressure.  27:123-124. 2018
    2018 O-Linked β-N-Acetylglucosamine Modification of A20 Enhances the Inhibition of NF-κB (Nuclear Factor-κB) Activation and Elicits Vascular Protection After Acute Endoluminal Arterial Injury.Arteriosclerosis, Thrombosis, and Vascular Biology.  38:1309-1320. 2018
    2018 Reply.Journal of Hypertension.  36:1423-1424. 2018
    2018 Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.Journal of Hypertension.  36:904-915. 2018
    2018 Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.Journal of Clinical Hypertension.  20:694-702. 2018
    2018 New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?Blood Pressure.  27:62-65. 2018
    2018 Hypertension.Nature Reviews Disease Primers.  4:18014. 2018
    2018 Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial).Hypertension.  71:848-857. 2018
    2018 Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants.PLoS ONE.  13:e0203305. 2018
    2018 What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?Journal of Hypertension.  36:37-40. 2018
    2017 Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies.Hypertension.  71:326-335. 2017
    2017 Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?Blood Pressure.  26:319-320. 2017
    2017 Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions.Blood Pressure.  27:1-2. 2017
    2017 VEGF nanoparticles repair the heart after myocardial infarction.AJP - Heart and Circulatory Physiology.  314:H278-H284. 2017
    2017 Risk stratification of sudden cardiac death in hypertension.Journal of Electrocardiology.  50:798-801. 2017
    2017 Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).Stroke.  48:3078-3085. 2017
    2017 Masked Hypertension.Current Hypertension Reports.  19:81. 2017
    2017 Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).American Journal of Kidney Diseases.  70:357-367. 2017
    2017 Effects of Intensive BP Control in CKD.Journal of the American Society of Nephrology.  28:2812-2823. 2017
    2017 Regression of Left Ventricular Mass After Bariatric Surgery.Current Hypertension Reports.  19:68. 2017
    2017 Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.Circulation.  136:798-812. 2017
    2017 Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.New England Journal of Medicine.  377:733-744. 2017
    2017 The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection.Scientific Reports.  7:7563. 2017
    2017 Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials.Blood Pressure.  26:257-258. 2017
    2017 White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.Hypertension.  70:645-651. 2017
    2017 Race and sex differences in ambulatory blood pressure measures among HIV+ adults.Journal of the American Society of Hypertension.  11:420-427.e3. 2017
    2017 The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke.Blood Pressure.  26:131-132. 2017
    2017 Hypertension in Women: Recent Advances and Lingering Questions.Hypertension.  70:19-26. 2017
    2017 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.American Journal of Hypertension.  30:518-523. 2017
    2017 Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.Current Hypertension Reports.  19:41. 2017
    2017 Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.Circulation: Heart Failure.  10. 2017
    2017 Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury Response.Stem Cells Translational Medicine.  6:1168-1177. 2017
    2017 The INTERSALT Study and the complex relationship between salt intake and blood pressure.Blood Pressure.  26:65-66. 2017
    2017 Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant.Hypertension.  69:827-835. 2017
    2017 The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association.European Heart Journal.  38:712-719. 2017
    2017 Hypertension and Its Complications in a Young Man With Autoimmune Disease.Hypertension.  69:536-544. 2017
    2017 Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension.Current Hypertension Reports.  19:18. 2017
    2017 The Global Burden of Disease Study 2015 and Blood Pressure.Blood Pressure.  26:1. 2017
    2017 On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension.Hypertension.  69:220-227. 2017
    2017 Association between chronic kidney disease and cancer mortality: A report from the ALLHAT.Clinical Nephrology.  87 (2017):11-20. 2017
    2017 Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.JAMA Internal Medicine.  177:67-76. 2017
    2016 123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?Journal of Nuclear Cardiology.  24:372-376. 2016
    2016 Assessment of vascular function in low socioeconomic status preschool children: a pilot study.Journal of the American Society of Hypertension.  11:101-109. 2016
    2016 Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Journal of the American Society of Hypertension.  10:930-938.e9. 2016
    2016 BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?Current Cardiology Reports.  18:98. 2016
    2016 Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? A Protagonist View From the SPRINT Trial (Systolic Blood Pressure Intervention Trial).Circulation.  134:1308-1310. 2016
    2016 Blood Pressure in 2016: increased impact factor and change of editors.Blood Pressure.  25:331-332. 2016
    2016 OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN.Journal of Hypertension.  34 Suppl 1:e244. 2016
    2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.Journal of Hypertension.  34 Suppl 1:e393. 2016
    2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.Journal of Hypertension.  34 Suppl 1 - ISH 2016 Abstract Book:e393. 2016
    2016 SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN?Journal of Hypertension.  34 Suppl 1:e366. 2016
    2016 SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN?Journal of Hypertension.  34 Suppl 1 - ISH 2016 Abstract Book:e366. 2016
    2016 The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.Controlled Clinical Trials.  50:238-244. 2016
    2016 Orthostatic changes in systolic blood pressure among SPRINT participants at baseline.Journal of the American Society of Hypertension.  10:847-856. 2016
    2016 Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.Hypertension.  68:995-1003. 2016
    2016 Cardiovascular care for older adults: hypertension and stroke in the older adult.Journal of Geriatric Cardiology.  13:373-379. 2016
    2016 Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.Journal of the American Medical Association.  315:2673-2682. 2016
    2016 HOPE-3 and SPRINT: two landmark trials with different outcomes?Journal of the American Society of Hypertension.  10:477-481. 2016
    2016 Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.Journal of the American Society of Hypertension.  10:493-499. 2016
    2016 Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.Hypertension.  67:1085-1092. 2016
    2016 Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial.Circulation Journal.  80:1404-1412. 2016
    2016 The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Hypertension.  68:39-45. 2016
    2016 Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.Journal of Hypertension.  34:1005-1010. 2016
    2016 The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.Blood Pressure.  25:276-279. 2016
    2016 Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement.American Journal of Medicine.  129:372-378. 2016
    2016 CardioPulse. The SPRINT trial results.European Heart Journal.  37:924-927. 2016
    2016 The SPRINT trial resultsEuropean Heart Journal.  37:925-927. 2016
    2016 Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat.AJP - Heart and Circulatory Physiology.  310:H705-H715. 2016
    2016 Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.Clinical Journal of the American Society of Nephrology.  11:471-480. 2016
    2016 Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial.Hypertension.  67:550-555. 2016
    2016 SPS3 Evidence Supports Intensive Blood Pressure Control.Circulation.  133:552-554. 2016
    2016 SPRINT Trial Results: Latest News in Hypertension Management.Hypertension.  67:263-265. 2016
    2016 Ambulatory Blood Pressure Monitoring in Individuals with HIV: A Systematic Review and Meta-Analysis.PLoS ONE.  11:e0148920. 2016
    2016 Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).American Journal of Cardiology.  117:105-115. 2016
    2016 Smad3-mSin3A-HDAC1 Complex is Required for TGF-β1-Induced Transcriptional Inhibition of PPARγ in Mouse Cardiac Fibroblasts.Cellular Physiology and Biochemistry.  40:908-920. 2016
    2016 The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg.Blood Pressure.  25:1-3. 2016
    2015 A Randomized Trial of Intensive versus Standard Blood-Pressure Control.New England Journal of Medicine.  373:2103-2116. 2015
    2015 Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.Journal of the American Society of Hypertension.  9:845-854. 2015
    2015 An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.Journal of the American Society of Hypertension.  9:769-779. 2015
    2015 Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial.Journal of the American Society of Hypertension.  9:670-679. 2015
    2015 Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study.Annals of Internal Medicine.  163:329-338. 2015
    2015 Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack.American Journal of Medicine.  128:707-14.e2. 2015
    2015 Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attackAmerican Journal of Medicine.  128:707-714.e2. 2015
    2015 Estrogen and Cardiovascular Disease: Is Timing Everything?American Journal of the Medical Sciences.  350:27-35. 2015
    2015 Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure.Hypertension.  66:126-133. 2015
    2015 Tribute: John H. Laragh, MD.Journal of the American Society of Hypertension.  9:500-501. 2015
    2015 Less-tight versus tight control of hypertension in pregnancyNew England Journal of Medicine.  372:2366-2368. 2015
    2015 Less-tight versus tight control of hypertension in pregnancy.New England Journal of Medicine.  372:2366-2367. 2015
    2015 Is blood pressure control for stroke prevention the correct goal? The lost opportunity of preventing hypertension.Stroke.  46:1595-1600. 2015
    2015 Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.Journal of the American Society of Hypertension.  9:453-498. 2015
    2015 Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.Hypertension.  65:1372-1407. 2015
    2015 Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.Journal of the American College of Cardiology.  65:1998-2038. 2015
    2015 Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.Circulation.  131:e435-e470. 2015
    2015 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.Journal of the American College of Cardiology.  65:1314-1321. 2015
    2015 Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.Journal of Human Hypertension.  29:241-246. 2015
    2015 New approaches in the treatment of hypertension.Circulation Research.  116:1074-1095. 2015
    2015 Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study.Journal of Biomedical Science and Engineering.  8:213-225. 2015
    2015 Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.European Heart Journal.  36:219-227. 2015
    2015 John H. Laragh, MDJournal of the American Society of Hypertension2015
    2014 Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries.Journal of the American Society of Hypertension.  8:898-908. 2014
    2014 Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease.Journal of Hypertension.  32:2479-2486. 2014
    2014 The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010.Journal of the American Society of Hypertension.  8:891-897. 2014
    2014 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.Journal of the American Society of Hypertension.  8:808-819. 2014
    2014 The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).Clinical Trials.  11:532-546. 2014
    2014 Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.Journal of the American College of Cardiology.  64:1071-1078. 2014
    2014 Low sodium intake--cardiovascular health benefit or risk?New England Journal of Medicine.  371:677-679. 2014
    2014 Guidelines for managing high blood pressure--reply.Journal of the American Medical Association.  312:295-296. 2014
    2014 Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors.Arteriosclerosis, Thrombosis, and Vascular Biology.  34:1477-1485. 2014
    2014 Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling.Arteriosclerosis, Thrombosis, and Vascular Biology.  34:1539-1547. 2014
    2014 Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.Journal of the American Society of Hypertension.  8:405-413. 2014
    2014 Proceedings from Duke resistant hypertension think tank.American Heart Journal.  167:775-88.e1. 2014
    2014 Renal denervation in treatment-resistant hypertension - Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials.Blood Pressure.  23:135-137. 2014
    2014 Updated guidelines for management of high blood pressure in Japan.Hypertension Research.  37:484-487. 2014
    2014 Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Journal of Clinical Hypertension.  16:323-330. 2014
    2014 Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.American Journal of Kidney Diseases.  63:781-788. 2014
    2014 A controlled trial of renal denervation for resistant hypertension.New England Journal of Medicine.  370:1393-1401. 2014
    2014 Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension?Hypertension.  63:e84. 2014
    2014 Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010.Journal of Clinical Hypertension.  16:270-276. 2014
    2014 Chlorthalidone versus hydrochlorothiazide in hypertension treatment: do we have the evidence to decide?American Journal of Kidney Diseases.  63:387-389. 2014
    2014 Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.Hypertension.  63:451-458. 2014
    2014 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).Journal of the American Medical Association.  311:507-520. 2014
    2014 Hypertension management by practice guidelines.Blood Pressure.  23:1-2. 2014
    2014 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (JNC 8)Journal of Cardiopulmonary Rehabilitation.  34:218-219. 2014
    2014 Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function.Journal of Hypertension.  32:174-180. 2014
    2014 Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010.PLoS ONE.  9:e105888. 2014
    2014 Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models.Mediators of Inflammation.  2014:353614. 2014
    2014 Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.Ethnicity and Disease.  24:41-47. 2014
    2014 Update on Clinical Guidelines for Treatment of HypertensionCurrent Cardiovascular Risk Reports.  8:1-8. 2014
    2013 Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?Journal of Clinical Hypertension.  15:941. 2013
    2013 Hypertension in women.Kidney International Supplements.  3:352-356. 2013
    2013 Novel strategies for treatment of resistant hypertension.Kidney International Supplements.  3:357-363. 2013
    2013 Revisiting the pre-hypertension debate: increasing evidence for treatment--or not?Blood Pressure.  22:344. 2013
    2013 Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.Journal of Clinical Hypertension.  15:825-832. 2013
    2013 The human side of failed hypertension treatment.Journal of Clinical Hypertension.  15:762-764. 2013
    2013 Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3.Blood Pressure.  22:279-281. 2013
    2013 Relationships between metrics of visit-to-visit variability of blood pressure.Journal of Human Hypertension.  27:589-593. 2013
    2013 Prevalence of apparent treatment-resistant hypertension among individuals with CKD.Clinical Journal of the American Society of Nephrology.  8:1583-1590. 2013
    2013 Endothelial cells overexpressing IL-8 receptor reduce cardiac remodeling and dysfunction following myocardial infarction.AJP - Heart and Circulatory Physiology.  305:H590-H598. 2013
    2013 2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines.Blood Pressure.  22:191-192. 2013
    2013 Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Journal of Clinical Hypertension.  15:542-554. 2013
    2013 Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.Journal of Clinical Hypertension.  15:584-592. 2013
    2013 Ovarian hormones and vascular disease.Current Opinion in Cardiology.  28:411-416. 2013
    2013 Primary cardiovascular prevention by Mediterranean diet - the PREDIMED trial.Blood Pressure.  22:129-130. 2013
    2013 Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.Hypertension.  61:977-986. 2013
    2013 Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).American Journal of Cardiology.  111:1131-1138. 2013
    2013 Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism.Chest.  143:978-983. 2013
    2013 Reply to Visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY study.Journal of Clinical Hypertension.  15:301. 2013
    2013 Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.European Heart Journal.  34:676-683. 2013
    2013 Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure.Journal of Clinical Hypertension.  15:112-117. 2013
    2013 Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.Journal of Clinical Hypertension.  15:92-100. 2013
    2013 The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study.Journal of Hypertension.  31:370-376. 2013
    2012 Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.Blood Pressure.  21:329-330. 2012
    2012 Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney diseaseKidney International Supplements.  2:337-414. 2012
    2012 Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure.Journal of Clinical Hypertension.  14:744-750. 2012
    2012 Direct renin inhibitors in hypertension - approaching the moment of truth.Blood Pressure.  21:267-268. 2012
    2012 Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.Journal of Clinical Hypertension.  14:694-700. 2012
    2012 Vasorelaxing effects of estetrol in rat arteries.Journal of Endocrinology.  215:97-106. 2012
    2012 Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction.AJP - Heart and Circulatory Physiology.  303:H513-H522. 2012
    2012 Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.Clinical Cardiology.  35:528-535. 2012
    2012 J Curve in Hypertension.Current Cardiovascular Risk Reports.  6:281-290. 2012
    2012 Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.Journal of Human Hypertension.  26:502-506. 2012
    2012 Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.American Journal of Cardiovascular Drugs.  12:233-243. 2012
    2012 Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: The trinity randomized, double-blind, 12-week, parallel-group studyAmerican Journal of Cardiovascular Drugs.  12:233-243. 2012
    2012 Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.Clinical Journal of the American Society of Nephrology.  7:989-1002. 2012
    2012 Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.Hypertension.  59:926-933. 2012
    2012 Transforming growth factor-β regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure.AJP - Lung Cellular and Molecular Physiology.  302:L857-L865. 2012
    2012 Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury.Circulation.  125:1533-1541. 2012
    2012 Management of hypertension in the elderly.Nature Reviews Cardiology.  9:286-296. 2012
    2012 Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.Journal of the American Society of Hypertension.  6:132-141. 2012
    2012 Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.Circulation: Cardiovascular Quality and Outcomes.  5:153-162. 2012
    2012 Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.Journal of Clinical Hypertension.  14:149-157. 2012
    2012 Within-visit variability of blood pressure and all-cause and cardiovascular mortality among US adults.Journal of Clinical Hypertension.  14:165-171. 2012
    2012 Antiplatelet therapy for transient ischemic attack.Journal of Clinical Hypertension.  14:103-111. 2012
    2012 Increased time varying heart rate and cardiovascular risk in hypertension: benefit of selective I((f)) channel inhibitor?Blood Pressure.  21:1-2. 2012
    2012 Renal Sympathetic Denervation for Treatment of Hypertension.Current Treatment Options in Cardiovascular Medicine2012
    2012 Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients.Journal of the American Society of Hypertension.  6:66-72. 2012
    2012 Estrogen modulates NFκB signaling by enhancing IκBα levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-β.PLoS ONE.  7:e36890. 2012
    2012 Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Journal of Clinical Hypertension.  14:20-31. 2012
    2012 Refractory hypertension: definition, prevalence, and patient characteristics.Journal of Clinical Hypertension.  14:7-12. 2012
    2011 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.Journal of Clinical Hypertension.  13:873-880. 2011
    2011 An appropriate SCORE to assess cardiovascular risk in hypertension?Blood Pressure.  20:320-321. 2011
    2011 Can catheter-based renal denervation be used safely and effectively to substantially reduce blood pressure in treatment-resistant hypertensive patients?Current Cardiology Reports.  13:478-480. 2011
    2011 Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling.AJP - Lung Cellular and Molecular Physiology.  301:L899-L907. 2011
    2011 Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care.Journal of Hypertension.  29:2332-2338. 2011
    2011 Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).Circulation.  124:1811-1818. 2011
    2011 Renal nerve ablation: emerging role in therapeutics.Blood Pressure.  20:253-255. 2011
    2011 cGMP inhibits TGF-beta signaling by sequestering Smad3 with cytosolic beta2-tubulin in pulmonary artery smooth muscle cells.Molecular Endocrinology -Baltimore-.  25:1794-1803. 2011
    2011 The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension.Journal of Hypertension.  29:1829-1836. 2011
    2011 Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice.Journal of Hypertension.  29:1810-1819. 2011
    2011 High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts: a plea for early drug treatment?Blood Pressure.  20:188-189. 2011
    2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.Journal of the American Society of Hypertension.  5:259-352. 2011
    2011 Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone.AJP - Lung Cellular and Molecular Physiology.  301:L125-L134. 2011
    2011 Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.Journal of the American Society of Hypertension.  5:249-258. 2011
    2011 Response to intervisit blood pressure variability and outcome: Is heart rate a missing confounder?Hypertension.  58. 2011
    2011 Antihypertensive therapy and cancer risks?Blood Pressure.  20:127-128. 2011
    2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Circulation.  123:2434-2506. 2011
    2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.Journal of the American College of Cardiology.  57:2037-2114. 2011
    2011 Rationale for the use of multiple blockers of the renin-angiotensin- aldosterone system in specific patient populationsTherapy.  8:227-236. 2011
    2011 The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.Blood Pressure Monitoring.  16:87-95. 2011
    2011 Treatment of high blood pressure in acute stroke--the SCAST study.Blood Pressure.  20:67-68. 2011
    2011 Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association.Journal of the American College of Cardiology.  57:1404-1423. 2011
    2011 Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.Circulation.  123:1243-1262. 2011
    2011 Hypertension in 2010: new challenges in blood pressure goals and assessment.Nature Reviews Cardiology.  8:73-75. 2011
    2011 The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994.Hypertension.  57:160-166. 2011
    2011 Adherence and persistence with taking medication to control high blood pressure.Journal of the American Society of Hypertension.  5:56-63. 2011
    2011 Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.Journal of Hypertension.  29:161-170. 2011
    2011 O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells.PLoS ONE.  6:e24021. 2011
    2010 Cardiovascular risks in HIV patients.Blood Pressure.  19:325-327. 2010
    2010 Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.Journal of Human Hypertension.  24:831-838. 2010
    2010 Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?Current Cardiology Reports.  12:450-463. 2010
    2010 Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports.Blood Pressure.  19:271-272. 2010
    2010 Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.Journal of Clinical Sleep Medicine.  6:363-368. 2010
    2010 Blood pressure variability: Emerging role in risk assessment and therapeutics.Blood Pressure.  19:209-211. 2010
    2010 Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.Journal of Human Hypertension.  24:532-537. 2010
    2010 Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.Clinical Therapeutics.  32:1252-1269. 2010
    2010 A STITCH saves time and lowers blood pressure.Current Hypertension Reports.  12:146-148. 2010
    2010 Blood Pressure celebrates 20 years of dedication to Nordic hypertension research.Blood Pressure.  19:130-131. 2010
    2010 C-reactive protein-mediated vascular injury requires complement.Arteriosclerosis, Thrombosis, and Vascular Biology.  30:1189-1195. 2010
    2010 Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?Journal of Clinical Hypertension.  12:422-430. 2010
    2010 The transcription factor ETS-1 mediates proinflammatory responses and neointima formation in carotid artery endoluminal vascular injury.Hypertension.  55:1381-1388. 2010
    2010 Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.Hypertension.  55:1137-1142. 2010
    2010 Blood pressure and migration.Blood Pressure.  19:65-66. 2010
    2010 ASH position paper: dietary approaches to lower blood pressure.Journal of the American Society of Hypertension.  4:79-89. 2010
    2010 Combination therapy in hypertension.Journal of the American Society of Hypertension.  4:90-98. 2010
    2010 Treatment of hypertension in patients with diabetes--an update.Journal of the American Society of Hypertension.  4:62-67. 2010
    2010 When and how to use self (home) and ambulatory blood pressure monitoring.Journal of the American Society of Hypertension.  4:56-61. 2010
    2010 Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction.Hypertension.  55:241-248. 2010
    2010 Hypertension research into the new millennium.Blood Pressure.  19:1-2. 2010
    2010 Inhibition of transforming growth factor-beta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart.AJP - Heart and Circulatory Physiology.  298:H424-H432. 2010
    2010 Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.Clinical and experimental hypertension.  32:499-503. 2010
    2010 Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex.Journal of Clinical Hypertension.  12:3-13. 2010
    2010 Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.Integrated Blood Pressure Control.  3:113-123. 2010
    2010 Prehypertension: epidemiology, consequences and treatment.Nature Reviews Nephrology.  6:21-30. 2010
    2009 EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics.Therapeutic Advances in Cardiovascular Disease.  3:429-439. 2009
    2009 Editorial: Critical aspects in hypertension diagnosis and treatmentBlood Pressure.  18:3-4. 2009
    2009 Reduction of blood pressure in patients with treatment-resistant hypertension.Expert Opinion on Pharmacotherapy.  10:2959-2971. 2009
    2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factorsVascular Health and Risk Management.  5:453-463. 2009
    2009 An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension.Journal of the American Society of Hypertension.  3:395-402. 2009
    2009 Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.Journal of Cardiovascular Pharmacology.  54:427-436. 2009
    2009 ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses: ReplyArchives of Internal Medicine -New Series-.  169:1810-1811. 2009
    2009 Critical aspects in hypertension diagnosis and treatment.Blood Pressure -Supplement-.  1:3-4. 2009
    2009 Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.Clinical and experimental hypertension.  31:572-584. 2009
    2009 A true champion of Hungarian kidney research and nephrology education--tribute to László Rosivall.Acta Physiologica Hungarica.  96:375-382. 2009
    2009 Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial.Hypertension.  54:475-481. 2009
    2009 Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.Journal of Clinical Hypertension.  11:475-482. 2009
    2009 Hypertension in the elderly.Clinics in Geriatric Medicine.  25:391-412. 2009
    2009 ASH Position Paper: Dietary approaches to lower blood pressure.Journal of Clinical Hypertension.  11:358-368. 2009
    2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.Therapeutics and Clinical Risk Management.  5:459-464. 2009
    2009 ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.Archives of Internal Medicine -New Series-.  169:832-842. 2009
    2009 Hormone therapy of premature ovarian failure: the case for "natural" estrogen.Hypertension.  53:745-746. 2009
    2009 Loss of Thy-1 inhibits alveolar development in the newborn mouse lung.AJP - Lung Cellular and Molecular Physiology.  296:L738-L750. 2009
    2009 Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension.Journal of Hypertension.  27:673-679. 2009
    2009 Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.Postgraduate Medicine.  121:25-39. 2009
    2009 Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.Journal of Hypertension.  27:567-574. 2009
    2009 Estrogen and mechanisms of vascular protection.Arteriosclerosis, Thrombosis, and Vascular Biology.  29:289-295. 2009
    2009 Sleep apnea, aldosterone, and resistant hypertension.Progress in Cardiovascular Diseases.  51:371-380. 2009
    2009 Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy.Journal of the American Society of Hypertension.  3:52-68. 2009
    2009 Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?Blood Pressure.  18:92-93. 2009
    2009 ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood Pressure.  18:4-6. 2009
    2009 Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.Blood Pressure.  18:348-361. 2009
    2009 Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.American Heart Journal.  157:177-184. 2009
    2009 Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system.AJP - Heart and Circulatory Physiology.  296:H13-H28. 2009
    2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.Vascular Health and Risk Management.  5:453-463. 2009
    2009 Should we treat prehypertension?Blood Pressure.  18:298-299. 2009
    2009 The J-curve phenomenon revisited.Blood Pressure.  18:168-170. 2009
    2008 Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.Advances in Therapy.  25:1288-1302. 2008
    2008 Hypertension in womenInternational Journal of Atherosclerosis.  3:138-145. 2008
    2008 More focus on therapeutic targets and improved tolerability in hypertension.Blood Pressure -Supplement-.  2:3-4. 2008
    2008 More focus on therapeutic targets and improved tolerability in hypertension.Blood Pressure -Supplement-.  2:3-4. 2008
    2008 Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.Journal of Clinical Hypertension.  10:911-921. 2008
    2008 Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?Cardiology Clinics.  26:527-535. 2008
    2008 Role of oxygen availability in CFTR expression and function.American Journal of Respiratory Cell and Molecular Biology.  39:514-521. 2008
    2008 ASH position paper: treatment of hypertension in patients with diabetes-an update.Journal of Clinical Hypertension.  10:707-713. 2008
    2008 Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?Current Opinion in Nephrology and Hypertension.  17:484-490. 2008
    2008 Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: American perspective.Pol Arch Med Wewn.  118:508-512. 2008
    2008 Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.Hypertension.  52:279-286. 2008
    2008 Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury.AJP - Heart and Circulatory Physiology.  295:H335-H342. 2008
    2008 Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute.Hypertension.  52:30-36. 2008
    2008 Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung.AJP - Lung Cellular and Molecular Physiology.  295:L86-L95. 2008
    2008 Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.Archives of Internal Medicine -New Series-.  168:1159-1164. 2008
    2008 Achieving better blood pressure control.Blood Pressure -Supplement-.  1:3-4. 2008
    2008 Achieving better blood pressure control.Blood Pressure -Supplement-.  1:3-4. 2008
    2008 Beyond brachial pressure effect.Current Hypertension Reports.  10:213-215. 2008
    2008 A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.Current Medical Research and Opinion.  24:1101-1114. 2008
    2008 Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.Hypertension.  51:1103-1108. 2008
    2008 Mechanisms and treatment of resistant hypertension.Journal of Clinical Hypertension.  10:239-244. 2008
    2008 Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts.Circulation Research.  102:185-192. 2008
    2008 Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension.Hypertension.  51:339-344. 2008
    2008 A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.Blood Pressure.  17:68-69. 2008
    2008 ASH 2008: "Living the Vision".Journal of the American Society of Hypertension.  2:54-55. 2008
    2008 Benefits of hypertension management in diabetes: an opportunity not to be missed.Blood Pressure.  17:248-249. 2008
    2008 Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.Blood Pressure.  17:260-269. 2008
    2008 Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent.American Journal of Pathology.  172:22-30. 2008
    2008 Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.Vascular Health and Risk Management.  4:653-664. 2008
    2008 Management of older hypertensive patients.Blood Pressure.  17:184-185. 2008
    2008 More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension.Blood Pressure.  17:132-133. 2008
    2008 Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions.Pediatric Research.  63:26-32. 2008
    2008 Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment.Blood Pressure.  17:5-6. 2008
    2007 Hypertension: What it is; What it isn't; How to think about it, to prevent it, and to manage itMedGenMed : Medscape general medicine.  9. 2007
    2007 Hypertension: what it is; what it isn't; how to think about it, to prevent it, and to manage it. Interview by George D. Lundberg.MedGenMed : Medscape general medicine.  9:56. 2007
    2007 Aldosterone excess and resistance to 24-h blood pressure control.Journal of Hypertension.  25:2131-2137. 2007
    2007 Dual inhibition of the renin system by aliskiren and valsartan.Lancet.  370:1126-1127. 2007
    2007 A good year.Journal of the American Society of Hypertension.  1:369-370. 2007
    2007 Renin inhibitors in the management of hypertension.Journal of Clinical Hypertension.  9:706-707. 2007
    2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.Lancet.  370:221-229. 2007
    2007 Are current guidelines optimal for treatment of blood pressure in patients with coronary artery disease?Current Hypertension Reports.  9:211-213. 2007
    2007 Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation.AJP - Heart and Circulatory Physiology.  292:H2607-H2612. 2007
    2007 Mechanisms and treatment of resistant hypertension.Arquivos Brasileiros de Cardiologia.  88:683-692. 2007
    2007 Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.Circulation.  115:2761-2788. 2007
    2007 A major paradigm shift.Journal of the American Society of Hypertension.  1:162-163. 2007
    2007 Aliskiren and valsartan for antihypertensive therapyACC Cardiosource Review Journal.  16:68. 2007
    2007 Endothelin-1 mediates hypoxia-induced increases in vascular collagen in the newborn mouse lung.Pediatric Research.  61:559-564. 2007
    2007 The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?Journal of Clinical Hypertension.  9:372-380. 2007
    2007 Does improving hypertension control involve more than just pills?Nature Clinical Practice Cardiovascular Medicine.  4:182-183. 2007
    2007 Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.Journal of the American College of Cardiology.  49:1230-1250. 2007
    2007 Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.Circulation.  115:1481-1501. 2007
    2007 Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries.Menopause.  14:251-260. 2007
    2007 An Open Letter to ASH Members.Journal of the American Society of Hypertension.  1:97-98. 2007
    2007 Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.Journal of Clinical Hypertension.  9:187-195. 2007
    2007 Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.Current Medical Research and Opinion.  23:259-270. 2007
    2007 ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells.Journal of applied physiology: respiratory, environmental and exercise physiology.  102:390-398. 2007
    2007 Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.Blood Pressure.  16:344-346. 2007
    2007 Blood pressure control--slowly getting there through new strategies?Blood Pressure.  16:68-71. 2007
    2007 Documentation of endpoint prevention with combination therapy in hypertension is urgently needed.Blood Pressure.  16:4-5. 2007
    2007 Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.Vascular Health and Risk Management.  3:299-305. 2007
    2007 Hypertension and cardiovascular disease: is arterial stiffness the heart of the matter?Blood Pressure.  16:236-237. 2007
    2007 JASH Inaugural Issue.Journal of the American Society of Hypertension.  1:2. 2007
    2007 New ESH/ESC guidelines signal progress in hypertension management.Blood Pressure.  16:132-134. 2007
    2007 The role of endothelin-1 in human hypertension.Clinical Hemorheology and Microcirculation.  37:157-178. 2007
    2007 Where are we going? Beyond JNC 7.Preventive Cardiology.  10:222-227. 2007
    2006 Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.Journal of Clinical Hypertension.  8:850-857. 2006
    2006 Is there a new treatment for hypertensive disease in the horizon? Role of soluble guanylate cyclase.Hypertension.  48:822-823. 2006
    2006 Proteasomal inhibition: A novel pathway for prevention of atherosclerosis and restenosisVascular Disease Prevention.  3:345-352. 2006
    2006 Women and hypertension: what did we learn from the Women's Health Initiative?Cardiology in Review.  14:267-275. 2006
    2006 Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro.Atherosclerosis.  188:292-300. 2006
    2006 Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.Clinical and Experimental Pharmacology and Physiology.  33:773-779. 2006
    2006 Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of Clinical Hypertension.  8:649-656. 2006
    2006 Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling.Life Sciences.  79:1357-1365. 2006
    2006 Treatment of isolated systolic hypertension in diabetes mellitus type 2.Diabetes, Obesity and Metabolism.  8:381-387. 2006
    2006 Salt Sensitivity, a Determinant of Blood Pressure, Cardiovascular Disease and SurvivalJournal of the American College of Nutrition.  25:247S-255S. 2006
    2006 Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival.Journal of the American College of Nutrition.  25:247S-255S. 2006
    2006 Feasibility of treating prehypertension with an angiotensin-receptor blocker.New England Journal of Medicine.  354:1685-1697. 2006
    2006 Pulsology rediscovered: commentary on the Conduit Artery Function Evaluation (CAFE) study.Circulation.  113:1162-1163. 2006
    2006 Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling.Journal of applied physiology: respiratory, environmental and exercise physiology.  100:564-571. 2006
    2006 American Society of Hypertension, Inc
Leadership MessageJournal of Clinical Hypertension.  8:904-905. 2006
    2006 Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?Blood Pressure.  15:323-324. 2006
    2006 Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity.AJP - Heart and Circulatory Physiology.  290:H295-H303. 2006
    2006 The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?Blood Pressure.  15:260-262. 2006
    2005 Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Expert Opinion on Emerging Drugs.  10:729-745. 2005
    2005 Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice.Arteriosclerosis, Thrombosis, and Vascular Biology.  25:2094-2099. 2005
    2005 The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.Journal of the American College of Cardiology.  46:770-775. 2005
    2005 Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe?Journal of Clinical Hypertension.  7:403-408. 2005
    2005 Ethnicity and blood pressure.Journal of Clinical Hypertension.  7:357-364. 2005
    2005 Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling.Pediatric Research.  57:631-636. 2005
    2005 Gender and blood pressure.Journal of Clinical Hypertension.  7:300-309. 2005
    2005 Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.Circulation.  111:1924-1931. 2005
    2005 Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.Hypertension.  45:580-585. 2005
    2005 The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.Journal of Clinical Hypertension.  7:152-158. 2005
    2005 New-onset diabetes in treated hypertensive patients--is it clinically significant? Roundtable discussion.Journal of Clinical Hypertension.  7:90-95. 2005
    2005 Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.Hypertension.  45:198-202. 2005
    2005 Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.American Journal of Hypertension.  18:287-294. 2005
    2005 Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide.American Journal of Cardiovascular Drugs.  5:17-22. 2005
    2005 Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.Hypertension.  45:46-52. 2005
    2004 Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.American Journal of Hypertension.  17:23S-30S. 2004
    2004 Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade.Journal of Clinical Hypertension.  6:699-705. 2004
    2004 Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling.Hypertension.  44:746-750. 2004
    2004 Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells.Journal of applied physiology: respiratory, environmental and exercise physiology.  97:1550-1558. 2004
    2004 Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries.Circulation.  110:1664-1669. 2004
    2004 Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.Journal of Hypertension.  22:1805-1811. 2004
    2004 Interview with Suzanne Oparil, MD. Interview by Marvin Moser, MD.Journal of Clinical Hypertension.  6:509-512. 2004
    2004 Hypertensive therapy: Part II.Circulation.  109:3081-3088. 2004
    2004 Hypertensive therapy: Part I.Circulation.  109:2953-2958. 2004
    2004 Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.Journal of Human Hypertension.  18:381-389. 2004
    2004 Evidence-based guidelines for cardiovascular disease prevention in women.Journal of the American College of Cardiology.  43:900-921. 2004
    2004 Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement.Arteriosclerosis, Thrombosis, and Vascular Biology.  24:e29-e50. 2004
    2004 Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women.Arteriosclerosis, Thrombosis, and Vascular Biology.  24:394-396. 2004
    2004 The impact of serum uric acid on cardiovascular outcomes in the LIFE study.Kidney International.  65:1041-1049. 2004
    2004 Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse.Cardiovascular Research.  61:771-779. 2004
    2004 Evidence-based guidelines for cardiovascular disease prevention in women.Circulation.  109:672-693. 2004
    2004 Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury.Circulation.  109:234-241. 2004
    2004 Essential hypertension in women.Blood Pressure.  13:272-278. 2004
    2004 Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.Blood Pressure.  13:376-384. 2004
    2003 Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.Annals of Internal Medicine.  139:901-906. 2003
    2003 Improving outcomes for women after coronary artery bypass grafting: a case for prevention.Journal of Thoracic and Cardiovascular Surgery.  126:1704-1706. 2003
    2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension.  42:1206-1252. 2003
    2003 Pathogenesis of hypertension.Annals of Internal Medicine.  139:761-776. 2003
    2003 The neointimal response to endovascular injury is increased in obese Zucker rats.Diabetes, Obesity and Metabolism.  5:415-423. 2003
    2003 Hormone replacement therapy and inflammation: interactions in cardiovascular disease.Hypertension.  42:657-663. 2003
    2003 Response to renin-angiotensin system antagonists in hypertensive black subjects.Journal of the American College of Cardiology.  42:1141. 2003
    2003 Comparison of the SCOPE and LIFE results [2] (multiple letters)Journal of Hypertension.  21:1772-1773. 2003
    2003 Comparison of the SCOPE and LIFE results.Journal of Hypertension.  21:1772-1773. 2003
    2003 Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.Clinical Therapeutics.  25:2388-2404. 2003
    2003 Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.Annals of Internal Medicine.  139:169-177. 2003
    2003 Fibroblast growth factor mediates hypoxia-induced endothelin-- a receptor expression in lung artery smooth muscle cells.Journal of applied physiology: respiratory, environmental and exercise physiology.  95:643-651. 2003
    2003 Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse.Hypertension.  42:88-95. 2003
    2003 The seventh report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 reportEvidence Based Eye Care.  4:179-181. 2003
    2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.Journal of the American Medical Association.  289:2560-2572. 2003
    2003 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.Hypertension.  41:1006-1009. 2003
    2003 Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice.Clinical and Experimental Pharmacology and Physiology.  30:343-349. 2003
    2003 Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.Journal of the American College of Cardiology.  41:1148-1155. 2003
    2003 Alpha2A-adrenergic receptors mediate sympathoinhibitory responses to atrial natriuretic peptide in the mouse anterior hypothalamic nucleus.Hypertension.  41:571-575. 2003
    2003 Secondary prevention of coronary heart disease in women: a call to action.Annals of Internal Medicine.  138:150-151. 2003
    2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of the American Medical Association.  288:2981-2997. 2002
    2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Journal of the American Medical Association.  288:2998-3007. 2002
    2002 Endothelin-A receptor blockade in porcine pulmonary hypertension.Pediatric Research.  52:913-921. 2002
    2002 Endothelin-A receptor blockade in porcine pulmonary hypertension.Pediatric Research.  52:913-921. 2002
    2002 Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.Journal of the American Medical Association.  288:1491-1498. 2002
    2002 Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.Journal of Hypertension.  20:1879-1886. 2002
    2002 Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro.Circulation.  106:854-859. 2002
    2002 Drugs targeting the renin-angiotensin-aldosterone system.Nature Reviews Drug Discovery.  1:621-636. 2002
    2002 Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE geneAJP - Heart and Circulatory Physiology.  282. 2002
    2002 Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANPAJP - Renal Physiology.  282. 2002
    2002 Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene.AJP - Heart and Circulatory Physiology.  282:H2254-H2258. 2002
    2002 Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?Current Hypertension Reports.  4:219-220. 2002
    2002 The effect of antihypertensive drugs on the fetusJournal of Human Hypertension.  16:293-298. 2002
    2002 Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists.Journal of Human Hypertension.  16 Suppl 2:S17-S23. 2002
    2002 The effect of antihypertensive drugs on the fetus.Journal of Human Hypertension.  16:293-298. 2002
    2002 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet.  359:1004-1010. 2002
    2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet.  359:995-1003. 2002
    2002 Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic miceHypertension.  39:214-218. 2002
    2002 Hormone replacement therapy and hypertension.Current Opinion in Nephrology and Hypertension.  11:229-235. 2002
    2002 Sex hormones and hypertension.Cardiovascular Research.  53:688-708. 2002
    2002 Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice.Hypertension.  39:214-218. 2002
    2002 Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP.AJP - Renal Physiology.  282:F220-F227. 2002
    2002 Are there meaningful differences between antihypertensive agents?Cardiology in Review.  19:1-5. 2002
    2002 Are there meaningful differences in blood pressure control with current antihypertensive agents?American Journal of Hypertension.  15:14S-21S. 2002
    2002 Interview: Suzanne Oparil, MDCardiology in Review.  19:5-6. 2002
    2001 Erratum: Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension (Journal of Clinical Hypertension (2001) vol. 3(5) (283-291, 318))Journal of Clinical Hypertension.  3:395. 2001
    2001 Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive ratsAJP - Regulatory, Integrative and Comparative Physiology.  281. 2001
    2001 Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats.AJP - Regulatory, Integrative and Comparative Physiology.  281:R1934-R1939. 2001
    2001 Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: evidence from the mouse carotid artery ligation model.Circulation.  104:2740-2745. 2001
    2001 Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cellsAJP - Lung Cellular and Molecular Physiology.  281. 2001
    2001 Efficacy of perindopril in the treatment of systemic hypertension.American Journal of Cardiology.  88:3i-12i. 2001
    2001 Hypertension. Introduction.American Journal of Cardiology.  88:1i-2i. 2001
    2001 Hypertension. Introduction.American Journal of Cardiology.  88. 2001
    2001 Efficacy of perindopril in the treatment of systemic hypertensionAmerican Journal of Cardiology.  88:3-12. 2001
    2001 The American journal of cardiology: IntroductionAmerican Journal of Cardiology.  88. 2001
    2001 Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.Journal of Clinical Hypertension.  3:283-318. 2001
    2001 What do international guidelines say about therapy?Journal of Hypertension -Supplement-.  19:S23-S31. 2001
    2001 Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone.Journal of Human Hypertension.  15:495-498. 2001
    2001 Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells.AJP - Lung Cellular and Molecular Physiology.  281:L155-L163. 2001
    2001 Cardiovascular effects of estrogen.American Journal of Hypertension.  14:186S-193S. 2001
    2001 Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs.Current Hypertension Reports.  3:227-228. 2001
    2001 Health outcomes associated with calcium antagonists.Current Hypertension Reports.  3:228-229. 2001
    2001 Primary aldosteronism: a practical approach to diagnosis and treatment.Journal of Clinical Hypertension.  3:189-195. 2001
    2001 Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension.American Journal of Cardiology.  87:721-726. 2001
    2001 Treating hypertension in the elderly--whom to treat, when, and with what?Journal of Clinical Hypertension.  3:103-109. 2001
    2001 Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula.Circulation.  103:1012-1016. 2001
    2001 Hormone replacement therapy and stroke: are the results surprising?Circulation.  103:620-622. 2001
    2000 Endothelin and pulmonary hypertensionJournal of Cardiovascular Pharmacology.  35. 2000
    2000 Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.American Journal of Cardiology.  86:1182-1187. 2000
    2000 Endothelial dysfunction in the pulmonary vascular bed.American Journal of the Medical Sciences.  320:223-232. 2000
    2000 Hypertension in women.Journal of Human Hypertension.  14:691-704. 2000
    2000 Factors affecting blood pressure responses to diet: the Vanguard study.American Journal of Hypertension.  13:956-965. 2000
    2000 Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life studyAmerican Journal of Hypertension.  13:899-906. 2000
    2000 Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.American Journal of Hypertension.  13:899-906. 2000
    2000 A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction.Archives of Internal Medicine -New Series-.  160:2150-2158. 2000
    2000 Effects of increased consumption of fluid milk on energy and nutrient intake, body weight, and cardiovascular risk factors in healthy older adults.Journal of The American Dietetic Association.  100:810-817. 2000
    2000 Estrogen attenuates integrin-beta(3)-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells.Circulation.  101:2949-2955. 2000
    2000 Antihypertensive drug therapy in the third millennium: are there benefits beyond blood pressure?Current Hypertension Reports.  2:291-294. 2000
    2000 Fenoldopam, a dopamine agonist, for hypertensive emergency: A multicenter randomized trialAcademic Emergency Medicine.  7:653-662. 2000
    2000 Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group.Academic Emergency Medicine.  7:653-662. 2000
    2000 Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model.Circulation.  101:2342-2344. 2000
    2000 Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery.American Journal of Cardiology.  85:1276-1279. 2000
    2000 Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries.Circulation.  101:1362-1365. 2000
    2000 Essential hypertension : part II: treatment.Circulation.  101:446-453. 2000
    2000 Essential hypertension. Part I: definition and etiology.Circulation.  101:329-335. 2000
    2000 Endothelin and pulmonary hypertension.Journal of Cardiovascular Pharmacology.  35:S49-S53. 2000
    2000 Newly emerging pharmacologic differences in angiotensin II receptor blockersAmerican Journal of Hypertension.  13. 2000
    2000 Newly emerging pharmacologic differences in angiotensin II receptor blockers.American Journal of Hypertension.  13:18S-24S. 2000
    2000 The organum vasculosum of the lamina terminalis regulates noradrenaline release in the anterior hypothalamic nucleus.Neuroscience.  99:149-156. 2000
    2000 [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].Drugs.  59 Spec No 2:25-37. 2000
    1999 Bradykinin in the heart: friend or foe?Circulation.  100:2305-2307. 1999
    1999 Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries.Cardiovascular Research.  44:608-614. 1999
    1999 Harriet Pearson Dustan.Circulation.  100:2122-2123. 1999
    1999 Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.American Journal of Cardiology.  84:35S-41S. 1999
    1999 Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease.American Journal of Clinical Nutrition.  70:881-887. 1999
    1999 Treating multiple-risk hypertensive populations.American Journal of Hypertension.  12:121S-129S. 1999
    1999 Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro.Circulation.  100:1639-1645. 1999
    1999 Dietary changes favorably affect bone remodeling in older adults.Journal of The American Dietetic Association.  99:1228-1233. 1999
    1999 Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat.Journal of Molecular and Cellular Cardiology.  31:1927-1936. 1999
    1999 Nutritionally complete prepared meal plan to reduce cardiovascular risk factors: a randomized clinical trial.Journal of The American Dietetic Association.  99:1077-1083. 1999
    1999 2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor.Journal of Molecular and Cellular Cardiology.  31:1405-1412. 1999
    1999 Effects of candesartan cilexetil in patients with severe systemic hypertensionAmerican Journal of Cardiology.  84:289-293. 1999
    1999 Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.American Journal of Cardiology.  84:289-293. 1999
    1999 Proposed changes for NIH's Center for Scientific Review. Panel on Scientific Boundaries for Review. Center for Scientific Review Advisory Committee, National Institutes of Health.Science.  285:666-667. 1999
    1999 Proposed changes for NIH's center for scientific reviewScience.  285:666-667. 1999
    1999 Dietary salt reduction in hypertension--what is the evidence and why is it still controversial?Progress in Cardiovascular Diseases.  42:23-38. 1999
    1999 Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises.American Journal of Hypertension.  12:653-664. 1999
    1999 Hypertension in women.Journal of Clinical Endocrinology and Metabolism.  84:1862-1866. 1999
    1999 Recent outcome trials of newer antihypertensives.Current Hypertension Reports.  1:238-240. 1999
    1999 Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo.Circulation.  99:2583-2589. 1999
    1999 Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement.Circulation.  99:2480-2484. 1999
    1999 Guide to preventive cardiology for womenCirculation.  99:2480-2484. 1999
    1999 AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology.Journal of the American College of Cardiology.  33:1751-1755. 1999
    1999 Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women.Journal of Human Hypertension.  13:337-342. 1999
    1999 Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.American Journal of Therapeutics.  6:161-166. 1999
    1999 Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation.Journal of Molecular and Cellular Cardiology.  31:1033-1045. 1999
    1999 A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertensionAmerican Journal of Hypertension.  12:414-417. 1999
    1999 A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.American Journal of Hypertension.  12:414-417. 1999
    1999 Journal of Cardiovascular Pharmacology: IntroductionJournal of Cardiovascular Pharmacology.  33. 1999
    1999 Nontraditional cardiovascular risk factors.American Journal of the Medical Sciences.  317:193-207. 1999
    1999 Management of the hypertensive patient with coronary artery disease.American Journal of Hypertension.  12:56S-62S. 1999
    1999 Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes.Diabetes Care.  22:191-197. 1999
    1999 Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection.Hypertension.  33:170-176. 1999
    1999 Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.American Journal of Cardiology.  84:35-41. 1999
    1999 Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics.American Journal of Therapeutics.  6:19-24. 1999
    1999 Eprosartan versus enalapril in hypertensive patients with angiotensin- converting enzyme inhibitor-induced coughCurrent Therapeutic Research.  60:1-14. 1999
    1999 Guide to preventive cardiology for womenJournal of the American College of Cardiology.  33:1751-1755. 1999
    1999 Long-term morbidity and mortality trials with amlodipine.Journal of Cardiovascular Pharmacology.  33 Suppl 2:S1-S6. 1999
    1999 Management of the hypertensive patient with coronary artery diseaseAmerican Journal of Hypertension.  12:56S-62S. 1999
    1999 Treating multiple-risk hypertensive populationsAmerican Journal of Hypertension.  12:121-129. 1999
    1998 Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.Hypertension.  32:989-997. 1998
    1998 Healthier diets improve quality of life while reducing cardiovascular disease risk factorsDisease Management and Clinical Outcomes.  1:106-113. 1998
    1998 Case studyAmerican Journal of Hypertension.  11. 1998
    1998 Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker.Clinical Therapeutics.  20:1106-1114. 1998
    1998 The Sexual Dimorphism of High Blood Pressure.Cardiology in Review.  6:356-363. 1998
    1998 The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study.American Journal of Hypertension.  11:192S-194S. 1998
    1998 Effects of Candesartan cilexetil in patients with systemic hypertensionAmerican Journal of Cardiology.  82:961-965. 1998
    1998 Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.American Journal of Cardiology.  82:961-965. 1998
    1998 Garlic prevents hypoxic pulmonary hypertension in ratsAJP - Lung Cellular and Molecular Physiology.  275. 1998
    1998 Garlic prevents hypoxic pulmonary hypertension in rats.American Journal of Physiology.  275:L283-L287. 1998
    1998 Pathophysiology of sudden coronary death in women. Implications for prevention.Circulation.  97:2103-2105. 1998
    1998 An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.Clinical Therapeutics.  20:398-409. 1998
    1998 Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).Cardiology.  89:271-276. 1998
    1998 Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.American Journal of Hypertension.  11:88S-94S. 1998
    1998 Managing the patient with hard-to-control hypertension.American Family Physician.  57:1007-1020. 1998
    1998 An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartanClinical Therapeutics.  20:398-409. 1998
    1998 Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE studyHypertension.  32:989-997. 1998
    1998 Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertensionAmerican Journal of Hypertension.  11:31-40. 1998
    1998 Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension.American Journal of Hypertension.  11:31-40. 1998
    1998 Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertensionAmerican Journal of Hypertension.  11:88S-94S. 1998
    1997 Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerationsAJP - Heart and Circulatory Physiology.  273. 1997
    1997 Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic miceAJP - Lung Cellular and Molecular Physiology.  273. 1997
    1997 No role for NO in estrogen-mediated vasoprotection?Circulation.  96:2769-2771. 1997
    1997 Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations.American Journal of Physiology.  273:H1769-H1774. 1997
    1997 Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice.American Journal of Physiology.  273:L848-L855. 1997
    1997 Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogsAJP - Heart and Circulatory Physiology.  273. 1997
    1997 A 42-year-old man with hypertension.Journal of the American Medical Association.  278:1015-1021. 1997
    1997 Estrogen restores endothelial cell function in an experimental model of vascular injury.Circulation.  96:1624-1630. 1997
    1997 Antihypertensive effects of mibefradil in the treatment of mild-to- moderate systemic hypertensionAmerican Journal of Cardiology.  80. 1997
    1997 Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.American Journal of Cardiology.  80:12C-19C. 1997
    1997 Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertensionAmerican Journal of Hypertension.  10:735-742. 1997
    1997 Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet.American Journal of Clinical Nutrition.  66:373-385. 1997
    1997 Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs.American Journal of Physiology.  273:H961-H970. 1997
    1997 Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.Journal of Clinical Investigation.  100:253-258. 1997
    1997 Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function.Hypertension.  30:128-133. 1997
    1997 Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.American Journal of Hypertension.  10:735-742. 1997
    1997 The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.American Journal of Hypertension.  10:705-713. 1997
    1997 The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.Journal of Cardiovascular Pharmacology.  29:713-725. 1997
    1997 High blood pressure in women.International Journal of Fertility and Womens Medicine.  42:198-205. 1997
    1997 Scientists' statement regarding data on the sodium-hypertension relationship and sodium health claims on food labeling.Nutrition Reviews.  55:172-175. 1997
    1997 Gender and cardiovascular disease recent insights.Trends in Cardiovascular Medicine.  7:94-100. 1997
    1997 Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment.Circulation.  95:1301-1307. 1997
    1997 ALLHAT and calcium channel blockers [3]American Journal of Hypertension.  10:142-143. 1997
    1997 Nutritional management of cardiovascular risk factors. A randomized clinical trial.Archives of Internal Medicine -New Series-.  157:169-177. 1997
    1997 ALLHAT and calcium channel blockers. ALLHAT Research Group.American Journal of Hypertension.  10:142-143. 1997
    1997 Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients.American Journal of Hypertension.  10:68-76. 1997
    1997 Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene functionHypertension.  30:128-133. 1997
    1997 Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742))American Journal of Hypertension.  10:1081. 1997
    1997 Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertensionDrugs of Today.  33:729-738. 1997
    1997 The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methodsAmerican Journal of Hypertension.  10:705-713. 1997
    1997 The expanding role of calcium antagonists in cardiovascular diseaseClinical Therapeutics.  19:1-2. 1997
    1997 Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertensionCurrent Therapeutic Research.  58:930-943. 1997
    1996 Hypoxia decreases atrial natriuretic peptide clearance receptor (ANP-CR) gene expression in peripheral organs, but not in the brain, of ratsFederation proceedings.  10. 1996
    1996 Hypoxia stimulates human preproendothelin-1 (PPET-1) promoter activity in transgenic miceFederation proceedings.  10. 1996
    1996 Identification of the hypoxia-responsive element in the 5′ flanking region of human endothelin-1 geneFederation proceedings.  10. 1996
    1996 Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared diet.American Journal of Clinical Nutrition.  64:935-943. 1996
    1996 Selective enhancement of angiotensin converting enzyme (ACE) gene expression in the heart during the development and maintenance of pressure overload cardiac hypertrophyFederation proceedings.  10. 1996
    1996 Tbc11251, a highly selective endothelin-a receptor antagonist. prevents and reverses acute hypoxia-fnduced pulmonary hypertension in the ratFederation proceedings.  10. 1996
    1996 Atrial natriuretic peptide regulation of noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats.Journal of Clinical Investigation.  98:2060-2065. 1996
    1996 Classic papers symposium of the Southern Clinical Research meetings: white coat hypertension--fact or fancy?American Journal of the Medical Sciences.  312:219-220. 1996
    1996 Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery.Circulation.  94:2221-2227. 1996
    1996 Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension.Hypertension.  28:335-340. 1996
    1996 The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.Clinical Therapeutics.  18:797-810. 1996
    1996 Purification and assay methods for angiotensin-converting enzyme.Chromatographic reviews.  743:105-122. 1996
    1996 Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.Clinical Therapeutics.  18:608-625. 1996
    1996 Preventing heart attack and death in patients with coronary disease. Endorsed by the board of trustees of the American College of Cardiology.Cardio-vascular nursing.  32:26-28. 1996
    1996 Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension.Frontiers in Neuroendocrinology.  17:212-246. 1996
    1996 Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.American Journal of Hypertension.  9:342-360. 1996
    1996 Acute saline infusion decreases norepinephrine release in the anterior hypothalamic area.Hypertension.  27:578-583. 1996
    1996 Antihypertensive therapy in the era of evidence based medical practice: what to do until the facts are in.Current Opinion in Nephrology and Hypertension.  5:159-161. 1996
    1996 Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats.Hypertension.  27:297-302. 1996
    1996 Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery.Circulation.  93:577-584. 1996
    1996 17-β estradiol but not medroxyprogesterone inhibits neointima formation after balloon injury of rat carotid arteriesJournal of Investigative Medicine.  44. 1996
    1996 17-β estradiol inhibits restenosis after coronary angioplasty in pigsJournal of Investigative Medicine.  44. 1996
    1996 A-127722, an orally active antagonist of the endothelin-a receptor, retards the progression of chronic hypoxia induced pulmonary hypertension in the ratJournal of Investigative Medicine.  44. 1996
    1996 Antihypertensive therapy and atherosclerosis in coronary heart diseaseCardiovascular Risk Factors.  6:222-232. 1996
    1996 Cardiac renin angiotensin system in hypertrophy and the progression to heart failureHeart Failure Reviews.  1:63-72. 1996
    1996 Cardiovascular risk reduction in womenJournal of women's health / the official publication of the Society for the Advancement of Women's Health Research.  5:23-32. 1996
    1996 Estrogen, but not androgen, inhibits the proliferation of cultured vascular smooth muscle cells derived from male and female spontaneously hypertensive ratsJournal of Investigative Medicine.  44. 1996
    1996 Hypertension: Initial evaluationACC Current Journal Review.  5:60-62. 1996
    1996 Hypoxia decreases atrial natriuretic peptide clearance receptor gene expression in pulmonary vascular smooth muscle cells in situJournal of Investigative Medicine.  44. 1996
    1996 Hypoxia enhances promoter activity of human endothelin-1 gene in transgenic miceJournal of Investigative Medicine.  44. 1996
    1996 Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive ratsJournal of Investigative Medicine.  44. 1996
    1996 Phenotypic characterization of transgenic mice with "knockout" for the angiotensin converting enzymeJournal of Investigative Medicine.  44. 1996
    1996 Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)American Journal of Hypertension.  9:342-360. 1996
    1995 Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.Journal of applied physiology: respiratory, environmental and exercise physiology.  79:2122-2131. 1995
    1995 Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitationAJP - Heart and Circulatory Physiology.  269. 1995
    1995 Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation.American Journal of Physiology.  269:H2065-H2073. 1995
    1995 Racial differences in the pathogenesis of hypertension.American Journal of the Medical Sciences.  310 Suppl 1:S86-S90. 1995
    1995 ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat.American Journal of Physiology.  269:L690-L697. 1995
    1995 Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue.Biochemical Pharmacology.  50:1445-1450. 1995
    1995 Effects of dietary salt on angiotensin peptides in kidney.Journal of the American Society of Nephrology.  6:1209-1215. 1995
    1995 The elusive role of atrial natriuretic peptide in hypertension.Mayo Clinic Proceedings.  70:1015-1017. 1995
    1995 Calcium antagonists: Antihypertensive and vascular considerationsCardiovascular Reviews and Reports.  16. 1995
    1995 Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial.Journal of Cardiovascular Pharmacology.  26:471-476. 1995
    1995 Hypertension in postmenopausal women: pathophysiology and management.Current Opinion in Nephrology and Hypertension.  4:438-442. 1995
    1995 Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats.Hypertension.  26:285-289. 1995
    1995 Preventing heart attack and death in patients with coronary disease.Circulation.  92:2-4. 1995
    1995 SSCI Founders Medal recipient's address.American Journal of the Medical Sciences.  310:4-5. 1995
    1995 Fighting the NIH funding crisis.Circulation.  91:2502. 1995
    1995 Hypertensive crisis since FDR--a partial victory.New England Journal of Medicine.  332:1029-1030. 1995
    1995 Acute hypertension increases norepinephrine release in the anterior hypothalamic area.Hypertension.  25:828-833. 1995
    1995 Cardiovascular health at the crossroads: outlook for the 21st century. Presented at the 67th Scientific Sessions of the American Heart Association November 4, 1994 Dallas, Texas.Circulation.  91:1304-1310. 1995
    1995 Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia.American Journal of Physiology.  268:L328-L335. 1995
    1995 ET(A)-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in ratAJP - Lung Cellular and Molecular Physiology.  269. 1995
    1995 Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the ratAJP - Lung Cellular and Molecular Physiology.  268. 1995
    1995 Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat.American Journal of Physiology.  268:L95-100. 1995
    1995 Initial medication selection for treatment of high blood pressure.Journal of the American Board of Family Medicine.  8:70-72. 1995
    1995 Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxiaAJP - Lung Cellular and Molecular Physiology.  268. 1995
    1994 Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo.Circulation.  90:2468-2473. 1994
    1994 Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects.Journal of Hypertension.  12:1291-1296. 1994
    1994 Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia.Journal of applied physiology: respiratory, environmental and exercise physiology.  77:1451-1459. 1994
    1994 Sodium-proton (Na+/H+) exchange inhibition increases blood pressure in spontaneously hypertensive rat.American Journal of the Medical Sciences.  308:145-151. 1994
    1994 Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats.Hypertension.  24:1-7. 1994
    1994 Increased endothelin receptor gene expression in hypoxic rat lung.American Journal of Physiology.  266:L553-L560. 1994
    1994 Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations.Current Opinion in Nephrology and Hypertension.  3:195-199. 1994
    1994 Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat.American Journal of the Medical Sciences.  307 Suppl 1:S26-S37. 1994
    1994 Increased endothelin receptor gene expression in hypoxic rat lungAJP - Lung Cellular and Molecular Physiology.  266. 1994
    1994 Increased endothelin receptor gene expression in hypoxic rat lungAmerican Journal of Physiology.  266. 1994
    1994 The role of atrial natriuretic peptide and endothelin in hypoxia induced pulmonary hypertension.Chinese Journal of Physiology.  37:165-183. 1994
    1993 Normotensive blacks have heightened sympathetic response to cold pressor test.Hypertension.  22:801-805. 1993
    1993 Coarctation induces alterations in basement membranes in the cardiovascular system.Hypertension.  22:743-753. 1993
    1993 Report of the task force on children and youth. American Heart Association.Circulation.  88:2479-2486. 1993
    1993 Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats.Hypertension.  22:285-291. 1993
    1993 Presentation of the Southern Society for Clinical Investigation Founder's Medal to Dr. James A. Pittman, Jr.American Journal of the Medical Sciences.  306:1-3. 1993
    1993 Simplified method for quantitation of angiotensin peptides in tissue.J Chromatogr.  614:19-25. 1993
    1993 Antihypertensive therapy--efficacy and quality of life.New England Journal of Medicine.  328:959-961. 1993
    1993 Nitric oxide mediates immune dysfunction in the spontaneously hypertensive rat.Hypertension.  21:185-194. 1993
    1993 Report of the task force on children and youthCirculation.  88:2479-2485. 1993
    1992 Blocking hypothalamic AT1 receptors lowers blood pressure in salt-sensitive rats.Hypertension.  20:755-762. 1992
    1992 Normobaric hypoxia stimulates endothelin-1 gene expression in the ratAmerican Journal of Physiology.  263. 1992
    1992 Normobaric hypoxia stimulates endothelin-1 gene expression in the rat.American Journal of Physiology.  263:R1260-R1264. 1992
    1992 Ganglion atrial natriuretic peptide in NaCl sensitive spontaneously hypertensive rats.American Journal of Hypertension.  5:806-810. 1992
    1992 Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells.American Journal of Physiology.  263:C743-C749. 1992
    1992 Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat.Hypertension.  20:374-379. 1992
    1992 Preparative isolation of angiotensin-converting enzyme from human lungJournal of Chromatography - Biomedical Applications.  579:63-71. 1992
    1992 Preparative isolation of angiotensin-converting enzyme from human lung.J Chromatogr.  579:63-71. 1992
    1992 Salt supplementation does not alter the pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii.Hypertension.  20:242-246. 1992
    1992 Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats.American Journal of the Medical Sciences.  304:14-19. 1992
    1992 Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats.Hypertension.  19:456-463. 1992
    1992 Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus.Hypertension.  19:475-481. 1992
    1992 Neuronal control of the kidney: contribution to hypertension.Canadian Journal of Physiology and Pharmacology.  70:759-770. 1992
    1992 Isolation of two distinct type I angiotensin II receptor genes.Biochemical and Biophysical Research Communications.  184:1067-1073. 1992
    1992 Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats.American Journal of Hypertension.  5:210-218. 1992
    1992 Quantitation of hypothalamic atrial natriuretic peptide messenger RNA in hypertensive rats.Hypertension.  19:296-300. 1992
    1992 Sex difference in blood pressure of spontaneously hypertensive rats influenced by perinatal NaCl exposure.Physiology and Behavior.  51:449-455. 1992
    1992 Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii.Hypertension.  19:198-205. 1992
    1992 Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cellsAmerican Journal of Physiology.  263. 1992
    1992 Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive ratsAmerican Journal of Hypertension.  5:210-218. 1992
    1992 Spontaneously hypertensive rat: Lymphoid depression is age dependent and mediated via a mononuclear cell subpopulationAmerican Journal of Physiology.  262. 1992
    1992 Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation.American Journal of Physiology.  262:R1-R7. 1992
    1991 Atrial natriuretic peptide inhibits sympathetic outflow in NaCl-sensitive spontaneously hypertensive rats.Journal of Hypertension.  9:1177-1185. 1991
    1991 Decreased norepinephrine release in anterior hypothalamus of NaCl-sensitive spontaneously hypertensive rats during high NaCl intake.Brain Research.  565:135-141. 1991
    1991 Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats.Journal of applied physiology: respiratory, environmental and exercise physiology.  71:807-814. 1991
    1991 Intrahypothalamic clonidine infusion prevents NaCl-sensitive hypertension.Hypertension.  18:224-229. 1991
    1991 Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effectsAmerican Journal of Clinical Nutrition.  54. 1991
    1991 Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effects.American Journal of Clinical Nutrition.  54:227S-236S. 1991
    1991 The calcium antagonists in the 1990s. An overview.American Journal of Hypertension.  4:396S-405S. 1991
    1991 Antihypertensive effect of cicletanine is exaggerated in NaCl-sensitive hypertension.American Journal of the Medical Sciences.  301:383-389. 1991
    1991 Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats.American Journal of Hypertension.  4:449-455. 1991
    1991 Treatment of hypertensive crisis.New England Journal of Medicine.  324:992-994. 1991
    1991 High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats.Hypertension.  17:363-368. 1991
    1991 Neuronal angiotensin-converting enzyme (ACE) gene expression is increased by converting enzyme inhibitors (CEI).Molecular and Cellular Neuroscience.  2:13-20. 1991
    1991 Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive ratsAmerican Journal of Hypertension.  4:449-455. 1991
    1991 The calcium antagonists in the 1990s an overviewAmerican Journal of Hypertension.  4:396S-405S. 1991
    1990 Blockade of endogenous anterior hypothalamic atrial natriuretic peptide with monoclonal antibody lowers blood pressure in spontaneously hypertensive rats.Journal of Clinical Investigation.  86:1985-1990. 1990
    1990 Noninvasive assessment of renal artery stenosis by combined conventional and color Doppler ultrasound.Echocardiography.  7:679-688. 1990
    1990 Treatment of hypertensive crisis.New England Journal of Medicine.  323:1177-1183. 1990
    1990 Dietary Ca2+ increases natriuretic and diuretic responses to volume loading in NaCl-sensitive spontaneously hypertensive rats.Journal of Hypertension.  8:947-951. 1990
    1990 Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats.Hypertension.  16:468-471. 1990
    1990 Lesions of the anterior hypothalamic area increase arterial pressure in NaCl-sensitive spontaneously hypertensive rats.Journal of the Autonomic Nervous System -Amsterdam-.  31:21-29. 1990
    1990 In ReplyJournal of the American Medical Association.  264:972-973. 1990
    1990 Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism.American Journal of Hypertension.  3:179S-188S. 1990
    1990 High-performance liquid chromatographic determination of amiloride and its analogues in rat plasma.J Chromatogr.  529:201-209. 1990
    1990 NaCl does not affect hypothalamic noradrenergic input in deoxycorticosterone acetate/NaCl and Dahl salt-sensitive rats.Hypertension.  16:55-62. 1990
    1990 Atrial natriuretic peptide clearance receptor agonist lowers pulmonary pressure in hypoxic rats.Journal of applied physiology: respiratory, environmental and exercise physiology.  68:2413-2418. 1990
    1990 An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy.Journal of the American Medical Association.  263:1507-1512. 1990
    1990 Atrial natriuretic factor prevents NaCl-sensitive hypertension in spontaneously hypertensive rats.Hypertension.  15:170-176. 1990
    1990 Vascular effects of kinins in trout and bradykinin metabolism by perfused gill.American Journal of Physiology.  258:R515-R522. 1990
    1990 Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia.Journal of Clinical Investigation.  85:115-120. 1990
    1990 Changes in cerebrospinal fluid Na+ concentration do not underlie hypertensive responses to dietary NaCl in spontaneously hypertensive rats.Brain Research.  506:149-152. 1990
    1990 Dietary ca2+prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanismAmerican Journal of Hypertension.  3:179S-188S. 1990
    1990 High-performance liquid chromatographic determination of amiloride and its analogues in rat plasmaJournal of Chromatography - Biomedical Applications.  529:201-209. 1990
    1990 Vascular effects of kinins in trout and bradykinin metabolism by perfused gillAmerican Journal of Physiology.  258. 1990
    1989 Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease.American Journal of the Medical Sciences.  298:397-401. 1989
    1989 Impaired reflex response to volume expansion in NaCl-sensitive spontaneously hypertensive rats.Hypertension.  14:518-523. 1989
    1989 Atrial natriuretic factor in NaCl-sensitive and NaCl-resistant spontaneously hypertensive rats.Hypertension.  14:404-412. 1989
    1989 Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide.American Journal of the Medical Sciences.  298:227-236. 1989
    1989 Dietary Ca2+ prevents NaCl-induced exacerbation of hypertension and increases hypothalamic norepinephrine turnover in spontaneously hypertensive rats.Journal of Hypertension.  7:711-719. 1989
    1989 Renal nerve contribution to NaCl-exacerbated hypertension in spontaneously hypertensive rats.Hypertension.  14:184-190. 1989
    1989 Central mechanisms of hypertension.American Journal of Hypertension.  2:477-485. 1989
    1989 Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats.American Journal of Hypertension.  2:435-439. 1989
    1989 Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis.American Journal of Physiology.  256:C1231-C1238. 1989
    1989 Hypertension.Disease-A-Month.  35:133-232. 1989
    1989 Purification of angiotensin-converting enzyme by gel high-performance liquid chromatography.J Chromatogr.  461:271-275. 1989
    1989 A simple method for concentration of biogenic amines and their metabolites from biological samples for analysis by HPLC-EC.Life Sciences.  44:1207-1213. 1989
    1989 Central mechanisms of hypertensionAmerican Journal of Hypertension.  2:477-485. 1989
    1989 Dietary Ca2+ supplementation prevents the exaggerated responsiveness of anterior hypothalamic alpha 2-adrenoceptors in NaCl-loaded spontaneously hypertensive rats.Journal of Cardiovascular Pharmacology.  13:162-167. 1989
    1989 Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia.Journal of applied physiology: respiratory, environmental and exercise physiology.  66:151-160. 1989
    1989 HypertensionDisease-A-Month.  35:138-232. 1989
    1989 Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesisAmerican Journal of Physiology.  256. 1989
    1988 Enhanced cold pressor response in spontaneously hypertensive rats on high-NaCl dietAmerican Journal of Physiology.  255. 1988
    1988 Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure.Lung.  166:209-219. 1988
    1988 The use of complementary peptides in the purification of an angiotensin II binding protein.Journal of Hypertension -Supplement-.  6:S404-S407. 1988
    1988 Enhanced cold pressor response in spontaneously hypertensive rats on high-NaCl diet.American Journal of Physiology.  255:H1018-H1023. 1988
    1988 Atrial natriuretic peptide lowers pulmonary arterial pressure in hypoxia-adapted rats.Journal of applied physiology: respiratory, environmental and exercise physiology.  65:1729-1735. 1988
    1988 Hypothalamic microinjection of alpha 2-adrenoceptor agonists causes greater sympathoinhibition in spontaneously hypertensive rats on high NaCl diets.Journal of Hypertension.  6:805-813. 1988
    1988 Treating the older hypertensive patient-an overviewAmerican Journal of Medicine.  85:1. 1988
    1988 Effect of steric exclusion on the separation of proteins by hydrophilic size-exclusion chromatography.J Chromatogr.  445:29-36. 1988
    1988 Altered angiotensin-converting enzyme in lung and extrapulmonary tissues of hypoxia-adapted rats.Journal of applied physiology: respiratory, environmental and exercise physiology.  65:218-227. 1988
    1988 Effect of steric exclusion on the separation of proteins by hydrophilic size-exclusion chromatography.Journal of chromatography.  445:29-36. 1988
    1988 Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive rats.American Journal of the Medical Sciences.  296:78-83. 1988
    1988 High NaCl diet increases anterior hypothalamic alpha 2-adrenoceptors in SHR.Brain Research.  451:77-84. 1988
    1988 Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats.Hypertension.  11:739-744. 1988
    1988 Central serotonergic alterations in deoxycorticosterone acetate/NaCl (DOCA/NaCl)-induced hypertension.Neuropharmacology.  27:417-426. 1988
    1988 Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA.Proceedings of the National Academy of Sciences.  85:2518-2522. 1988
    1988 The neural basis of salt sensitivity in the rat: altered hypothalamic function.American Journal of the Medical Sciences.  295:360-369. 1988
    1988 Captopril and the response to stress in the spontaneously hypertensive rat.Hypertension.  11:I144-I147. 1988
    1988 Captopril and the response to stress in the spontaneously hypertensive ratHypertension.  11:I-144-I-147. 1988
    1988 Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia-adapted rats.Transactions of the Association of American Physicians.  101:185-192. 1988
    1988 Current and future role of catapresan in the treatment of hypertensionRound Table Series- Royal Society of Medicine.  1-47. 1988
    1988 Genetic basis of NaCl-sensitive hypertension.Journal of Cardiovascular Pharmacology.  12 Suppl 3:S56-S69. 1988
    1988 High NaCl diet reduces hypothalamic norepinephrine turnover in hypertensive rats.Hypertension.  11:55-62. 1988
    1988 Hypoxia-induced oxygen tolerance: maintenance of endothelial metabolic function.Experimental Lung Research.  14 Suppl:887-896. 1988
    1988 Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive ratsHypertension.  11:739-744. 1988
    1988 Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure.Lung.  166:209-219. 1988
    1988 Perioperative red blood cell transfusionJournal of the American Medical Association.  260:2700-2703. 1988
    1988 Rapid communication: Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive ratsAmerican Journal of the Medical Sciences.  296:78-83. 1988
    1987 Antihypertensive effect of enalapril in essential hypertension: role of prostacyclin.American Journal of the Medical Sciences.  294:395-402. 1987
    1987 Failure of renal denervation to attenuate hypertension in Dahl NaCl-sensitive rats.Canadian Journal of Physiology and Pharmacology.  65:2428-2432. 1987
    1987 Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat of the Okamoto strain (SHR). II. The central nervous system (CNS).Brain Research Bulletin.  19:525-534. 1987
    1987 Hypoxia-induced inhibition of converting enzyme activity: role in vascular regulation.Journal of applied physiology: respiratory, environmental and exercise physiology.  63:1012-1018. 1987
    1987 Spontaneously hypertensive rats exhibit reduced hypothalamic noradrenergic input after NaCl loading.Hypertension.  10:313-320. 1987
    1987 Role of the dissolution mechanism in determining chromatographic separation of biogenic amines from their precursors and metabolites by HPLC-ECJournal of liquid chromatography.  10:2047-2053. 1987
    1987 The renal afferent nerves in the pathogenesis of hypertension.Canadian Journal of Physiology and Pharmacology.  65:1548-1558. 1987
    1987 Role of vasopressin in the cardiovascular effects of LY171555, a selective dopamine D2 receptor agonist: studies in conscious Brattleboro and Long-Evans rats.Journal of Pharmacology and Experimental Therapeutics.  242:143-151. 1987
    1987 Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat. I. The peripheral nervous system.Brain Research Bulletin.  19:101-108. 1987
    1987 Altered responsiveness of regional brain dopamine and DOPAC levels to systemic administration of quinpirole, a dopamine D2 agonist, in DOCA/NaCl-hypertensive rats.Brain Research.  413:15-22. 1987
    1987 De novo intrarenal formation of angiotensin II during control and enhanced renin secretion.American Journal of Physiology.  252:F1118-F1123. 1987
    1987 Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat.Hypertension.  9:III171-III175. 1987
    1987 Blunted responsiveness of posterior hypothalamic norepinephrine to quinpirole in DOCA/NaCl hypertensive rats.Brain Research Bulletin.  18:563-568. 1987
    1987 Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril.American Journal of Physiology.  252:H796-H806. 1987
    1987 Proteoglycans and hypertension: III: Aorta proteoglycans in Dahl salt-sensitive hypertensive rats.American Journal of the Medical Sciences.  293:171-176. 1987
    1987 Two renal alpha 2-adrenergic receptor sites revealed by p-aminoclonidine binding.American Journal of Physiology.  252:F283-F290. 1987
    1987 Enhanced response to the inhibitory action of LY171555, a dopamine D2-agonist, on in vivo striatal dopamine release in DOCA/NaCl-hypertensive rats.Brain Research.  400:225-231. 1987
    1987 Continuous intravenous infusion of LY171555, a potent selective D2 receptor agonist, lowers blood pressure in the conscious rat.Pharmacology.  35:194-202. 1987
    1987 De novo intrarenal formation of angiotensin II during control and enhanced renin secretionAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  252. 1987
    1987 Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive ratHypertension.  9:III-171-III-175. 1987
    1987 Hyperoxia-induced converting enzyme insufficiency in conscious rat: cardiovascular effects.Experimental Lung Research.  12:37-56. 1987
    1987 Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR)Clinical and experimental hypertension.  A9:1713-1731. 1987
    1987 Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR).Clinical and experimental hypertension.  9:1713-1731. 1987
    1987 Renal catecholamines and alpha 2-adrenergic receptors in salt-related and genetic hypertension.Pharmacology.  34:131-142. 1987
    1987 Sympathetic function in spontaneously hypertensive rats after chronic administration of captoprilAJP - Heart and Circulatory Physiology.  252. 1987
    1987 The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension.Journal of Cardiovascular Pharmacology.  9 Suppl 3:S43-S47. 1987
    1987 Two renal α2-adrenergic receptor sites revealed by p-aminoclonidine bindingAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  252. 1987
    1986 Transport and hydrolysis of glucagon in the proximal nephronAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  251. 1986
    1986 Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat.Journal of Pharmacology and Experimental Therapeutics.  239:426-432. 1986
    1986 The sympathetic nervous system in clinical and experimental hypertension.Kidney International.  30:437-452. 1986
    1986 Transport and hydrolysis of glucagon in the proximal nephron.American Journal of Physiology.  251:F460-F467. 1986
    1986 Effects of locally formed angiotensin II on renal hemodynamics.Federation proceedings.  45:1448-1453. 1986
    1986 Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia.Journal of applied physiology: respiratory, environmental and exercise physiology.  60:1121-1127. 1986
    1986 Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gill.American Journal of Physiology.  250:R532-R538. 1986
    1986 Mechanism of the pressor action of LY171555, a specific dopamine D2 receptor agonist, in the conscious rat.Journal of Pharmacology and Experimental Therapeutics.  236:735-742. 1986
    1986 Proteoglycans and hypertension. I. A biochemical and ultrastructural study of aorta glycosaminoglycans in spontaneously hypertensive rats.Collagen and related research.  6:77-101. 1986
    1986 Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gillAJP - Regulatory, Integrative and Comparative Physiology.  250. 1986
    1986 Genetic and salt-related alterations in monoamine neurotransmitters in Dahl salt-sensitive and salt-resistant rats.Pharmacology.  33:322-333. 1986
    1986 Increased vasopressinergic activity following DOCA administration in the rat.Brain Research Bulletin.  16:93-98. 1986
    1986 Sensory denervation of the kidney attenuates renovascular hypertension in the ratAJP - Heart and Circulatory Physiology.  250. 1986
    1986 Sensory denervation of the kidney attenuates renovascular hypertension in the rat.American Journal of Physiology.  250:H82-H86. 1986
    1985 Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive ratAJP - Heart and Circulatory Physiology.  18. 1985
    1985 Hyperresponsiveness of monoaminergic mechanisms in DOCA/NaCl hypertensive ratsAJP - Heart and Circulatory Physiology.  18. 1985
    1985 Enhanced depressor effect of muscimol in the DOCA/NaCl hypertensive rat: evidence for altered GABAergic activity in brain.Proceedings of the Society for Experimental Biology and Medicine.  180:277-283. 1985
    1985 Reverse-phase separation and electrochemical detection of neuropeptides.Peptides.  6:1173-1178. 1985
    1985 Hypertension in a 74-year-old man with hydronephrosis and coronary disease.Hypertension.  7:824-833. 1985
    1985 Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat.American Journal of Physiology.  249:H64-H70. 1985
    1985 Hyperresponsiveness of monoaminergic mechanisms in DOCA/NaCl hypertensive rats.American Journal of Physiology.  249:H71-H79. 1985
    1985 Pathogenesis of ventricular hypertrophy.Journal of the American College of Cardiology.  5:57B-65B. 1985
    1985 Hypertension in a 74-year-old man with hydronephrosis and coronary disease principal discussantHypertension.  7:824-833. 1985
    1985 Metabolism of angiotensin I by the trout gillFederation proceedings.  44. 1985
    1985 Morphologie substrates of sudden death: Questions and answersJournal of the American College of Cardiology.  5:79B-80B. 1985
    1985 Pathogenesis of ventricular hypertrophyJournal of the American College of Cardiology.  5:57B-65B. 1985
    1984 The role of the posterior hypothalamic area in the pathogenesis of hypertension in the spontaneously hypertensive rat.Brain Research.  324:51-58. 1984
    1984 Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive ratJournal of Hypertension.  2:63-66. 1984
    1984 Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat.Journal of Hypertension -Supplement-.  2:S63-S66. 1984
    1984 Myocardial cell hypertrophy or hyperplasiaHypertension.  6. 1984
    1984 Myocardial cell hypertrophy or hyperplasia.Hypertension.  6:III38-III43. 1984
    1984 Hormonal and haemodynamic responses to upper abdominal surgery during isoflurane and balanced anaesthesia.Canadian Anaesthetists' Society journal.  31:509-516. 1984
    1984 Renovascular hypertension in middle-aged females.The Alabama journal of medical sciences.  21:272-274. 1984
    1984 Subcellular sites of insulin hydrolysis in renal proximal tubulesAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  15. 1984
    1984 A randomized comparison of crystalloid and blood-containing cardioplegic solutions in 60 patients.Circulation.  69:973-982. 1984
    1984 Subcellular sites of insulin hydrolysis in renal proximal tubules.American Journal of Physiology.  246:F409-F416. 1984
    1984 Elevated catecholamines during cardiac surgery: consequences of reperfusion of the postarrested heart.American Journal of Cardiology.  53:722-728. 1984
    1984 Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat.Journal of Pharmacology and Experimental Therapeutics.  228:370-375. 1984
    1984 Basal release of striatal dopamine is higher in spontaneously hypertensive rats than in Wistar Kyoto controlsFederation proceedings.  43. 1984
    1984 Blood pressure oscillations in postsurgical hypertension during automatic controlFederation proceedings.  43. 1984
    1984 Comprehensive drug management of hypertension.Cardiovascular clinics.  14:73-91. 1984
    1984 Myocardial cell hypertrophy or hyperplasiaHypertension.  6:38-43. 1984
    1984 Renal handling of glucagonFederation proceedings.  43. 1984
    1984 Renal handling of glucagon and insulin.Contributions to Nephrology.  42:30-37. 1984
    1983 Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421).Journal of Laboratory and Clinical Medicine.  102:714-721. 1983
    1983 Altered vascular reactivity and baroreflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat.Hypertension.  5:689-700. 1983
    1983 Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril.Hypertension.  5:653-662. 1983
    1983 Enalapril in low-renin essential hypertension.Clinical Pharmacology and Therapeutics.  34:297-302. 1983
    1983 Intrarenal angiotensin I conversion at normal and reduced renal blood flow in the dog.American Journal of Physiology.  245:F408-F415. 1983
    1983 Kidney function and sodium handling in the pregnant spontaneously hypertensive rat.Hypertension.  5:498-506. 1983
    1983 Role of the renal nerves in the maintenance of DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion.Hypertension.  5:427-435. 1983
    1983 Central catecholamine depletion, vasopressin, and blood pressure in the DOCA/NaCl rat.American Journal of Physiology.  244:H807-H813. 1983
    1983 Effect of hypoxia on the conversion of angiotensin I to II in cultured porcine pulmonary endothelial cells.Biochemical Pharmacology.  32:1201-1205. 1983
    1983 Central catecholamine depletion, vasopressin, and blood pressure in the DOCA/NaCl ratAJP - Heart and Circulatory Physiology.  13. 1983
    1983 Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat (SHR)Federation proceedings.  42. 1983
    1982 Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats. Role of the sympathoadrenal system and vasopressin.Hypertension.  4:809-816. 1982
    1982 Differences between renal tubular processing of glucagon and insulinAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  11. 1982
    1982 Gallium 67 citrate scanning and serum angiotensin converting enzyme levels in sarcoidosis.Radiology.  144:895-899. 1982
    1982 Importance of the renal nerves in the pathogenesis of experimental hypertension.Hypertension.  4:III108-III114. 1982
    1982 The AFCR: is there life after 41?Clinical research.  30:316-321. 1982
    1982 The role of calcium in the control of renin release.Hypertension.  4:670-675. 1982
    1982 Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man.Circulation.  66:49-55. 1982
    1982 Decrease in hypothalamic norepinephrine content following renal denervation in the one-kidney, one clip Goldblatt hypertensive rat.Hypertension.  4:369-373. 1982
    1982 Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension.Hypertension.  4:166-174. 1982
    1982 Effect of hypoxia on the conversion of angiotensin I to II in the isolated perfused rat lung.Biochemical Pharmacology.  31:1375-1379. 1982
    1982 Differences between renal tubular processing of glucagon and insulin.American Journal of Physiology.  242:F112-F118. 1982
    1982 1982: A critical year for hypertensionHypertension.  4:1-2. 1982
    1982 Angiotensin-converting enzyme in serum and in bronchoalveolar lavage in sarcoidosis.Respiration.  43:153-157. 1982
    1982 Central sympathectomy with 6-hydroxydopamine prevents DOCA/NaCl hypertension by mechanisms independent of vasopressinClinical research.  30. 1982
    1982 Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat.Journal of Clinical Investigation.  69:55-62. 1982
    1982 Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat.Clinical and experimental hypertension.  4:707-716. 1982
    1982 Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip goldblatt hypertensive ratClinical and experimental hypertension.  A4:707-716. 1982
    1982 Importance of the renal Nerves in the Pathogenesis of Experimental HypertensionHypertension.  4:108-115. 1982
    1982 Importance of the renal nerves in established Two-Kidney, one clip goldblatt hypertensionHypertension.  4:166-174. 1982
    1982 Increased noradrenaline content of hypothalamic nuclei in association with worsening of hypertension after high sodium intake in the young spontaneously hypertensive ratClinical Science.  63. 1982
    1982 Increased noradrenergic activity in hypothalamic nuclei of spontaneously hypertensive rats on high sodium intakeClinical research.  30. 1982
    1982 Prevention of hypertension in the spontaneously hypertensive rat by chronic central administration of captoprilClinical research.  30. 1982
    1982 Review of therapeutic modalities acting directly via central pathwaysClinical and experimental hypertension.  A4:579-593. 1982
    1982 Review of therapeutic modalities acting directly via central pathways.Clinical and experimental hypertension.  4:579-593. 1982
    1982 Sodium-neural interactions in the development of spontaneous hypertensionClinical and experimental hypertension.  A4:751-760. 1982
    1982 Sodium-neural interactions in the development of spontaneous hypertension.Clinical and experimental hypertension.  4:751-760. 1982
    1981 Lofexidine and clonidine in moderate essential hypertension.Clinical Pharmacology and Therapeutics.  30:752-707. 1981
    1981 Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report.Critical Care Medicine.  9:651-654. 1981
    1981 Angiotensin II metabolism by tissues from developing rats.Pediatric Research.  15:1088-1092. 1981
    1981 Role of the renal nerves in the pathogenesis of one-kidney renal hypertension in the rat.Hypertension.  3:404-409. 1981
    1981 Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slices.American Journal of Physiology.  240:F501-F507. 1981
    1981 Hypertension and oral contraceptives.The Journal of cardiovascular medicine.  6:381-387. 1981
    1981 A progress report on hypertensionHypertension.  3:1-3. 1981
    1981 Catecholamine changes during cardiopulmonary bypass: The stress response and role of the lungs in modulating itAnesthesia and Analgesia.  60:272-273. 1981
    1981 Central effects of prostaglandin E2on blood pressure and plasma renin activity: Role of the sympathoadrenal system and vasopressinClinical research.  29. 1981
    1981 Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slicesAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  9. 1981
    1981 Prevention of DOCA/NaCl hypertension in the rat by central sympatholytic treatment is unrelated to vasopressinClinical research.  29. 1981
    1981 Renal function during reflexly activated catecholamine flow through an adrenorenal reteAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  9. 1981
    1981 Renal function during reflexly activated catecholamine flow through an adrenorenal rete.American Journal of Physiology.  240:F30-F37. 1981
    1980 Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat.Journal of Clinical Investigation.  66:971-978. 1980
    1980 Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors.American Journal of Cardiology.  46:559-565. 1980
    1980 NMR observation of altered sodium interaction with human erythrocyte membranes of essential hypertensives.Biochemical and Biophysical Research Communications.  96:514-521. 1980
    1980 Diurnal patterns and regulation of cortisol secretion in pregnancy.Journal of Clinical Endocrinology and Metabolism.  51:466-472. 1980
    1980 Hemodynamic response to vascular expansion following immunosympathectomy in spontaneously hypertensive rats.Hypertension.  2:304-310. 1980
    1980 Importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat.Hypertension.  2:266-273. 1980
    1980 Effect of acute hypoxia on the pulmonary conversion of angiotensin I to angiotensin II in dogs.Circulation Research.  46:221-226. 1980
    1980 Drug management of hypertensionCirculation.  61:210-212. 1980
    1980 Effect of molecular size and structure on renal tubular processing of peptidesCytobiologie.  22. 1980
    1980 Lofexidine in essential hypertension: Double blind comparison with clonidineClinical research.  28. 1980
    1980 Multiclinic double-blind evaluation of timolol combined with hydrochlorothiazide in essential hypertensionCurrent Therapeutic Research.  27:527-537. 1980
    1980 The first year of hypertensionHypertension.  2:1-2. 1980
    1979 Hypertrophy in the denervated heart: a comparison of central sympatholytic treatment with 6-hydroxydopamine and peripheral sympathectomy with nerve growth factor antiserum.American Journal of Cardiology.  44:970-978. 1979
    1979 Renal tubular transport and catabolism of proteins and peptides.Kidney International.  16:271-278. 1979
    1979 Mechanism of postarrhythmic renal vasoconstriction in the anesthetized dog.Journal of Clinical Investigation.  64:17-31. 1979
    1979 Regional myocyte size in normotensive and spontaneously hypertensive rats.Hypertension.  1:378-383. 1979
    1979 Clinical significance of serum angiotensin-converting enzyme levels in sarcoidosis.Journal of Laboratory and Clinical Medicine.  93:940-949. 1979
    1979 Mechanism for renal tubular handling of angiotensin.American Journal of Physiology.  236:F365-F372. 1979
    1979 Desoxycorticosterone in normal pregnancy. II. Cortisol-dependent fluctuations in free plasma desoxycorticosterone.American Journal of Obstetrics and Gynecology.  133:644-648. 1979
    1979 A simple method for determining the free cortisol index in plasma: measurements in human pregnancy.Journal of Laboratory and Clinical Medicine.  93:146-153. 1979
    1979 Effect of acute hypoxia on in-vivo conversion of angiotensin I to II in dogsFederation proceedings.  38. 1979
    1979 Hypertension: A new journalHypertension.  1:1-2. 1979
    1979 Mechanism for renal tubular handling of angiotensinAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  5. 1979
    1979 Mechanism of angiotensin I converting enzyme inhibition by SQ20,881 (less than Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) in vivo. Further evidence for extrapulmonary conversion.Hypertension.  1:13-22. 1979
    1979 Nomenclature for experimental renovascular hypertension. Report of the Nomenclature Committee of the Council for High Blood Pressure Research of the American Heart Association.Hypertension.  1:61. 1979
    1979 Renal tubular handling of glucagon and insulinClinical research.  27. 1979
    1979 The effect of renal denervation on the development of DOCA-salt hypertension in the ratClinical research.  27. 1979
    1978 Desoxycorticosterone in normal pregnancy. I. Sequential studies of the secretory patterns of desoxycorticosterone, aldosterone, and cortisol.American Journal of Obstetrics and Gynecology.  132:414-420. 1978
    1978 Myocardial hypertrophy and ventricular performance in the absence of hypertension in spontaneously hypertensive rats.Journal of Molecular and Cellular Cardiology.  10:689-693. 1978
    1978 Inhibition of renin release from rat kidney slices by the angiotensins.American Journal of Physiology.  235:F62-F68. 1978
    1978 Effects of constituent amino acids on tubular handling of microinfused angiotensin II.American Journal of Physiology.  234:F325-F331. 1978
    1978 Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive rats.Journal of Molecular and Cellular Cardiology.  10:302-305. 1978
    1978 Plasma angiotensin converting enzyme activity in mother and fetus.Journal of Clinical Endocrinology and Metabolism.  46:434-439. 1978
    1978 Calcium dependence of angiotensin II induced inhibition of renin release in vitroClinical research.  26. 1978
    1978 Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive ratsJournal of Molecular and Cellular Cardiology.  10:301-305. 1978
    1978 Effects of constituent amino acids on tubular handling of microinfused angiotensin IIAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  3. 1978
    1978 In vivo and in vitro conversion of des-1-Asp angiotensin I to angiotensin III.Biochemical Pharmacology.  27:2871-2877. 1978
    1978 Inhibition of renin release from rat kidney slices by the angiotensinAmerican Journal of Physiology - Renal Fluid and Electrolyte Physiology.  4. 1978
    1978 Report of the AFCR public policy committee: current legislative prioritiesClinical research.  26:330-332. 1978
    1978 Report of the AFCR public policy committee: current legislative prioritiesClinical research.  26:121-123. 1978
    1978 The mechanism of post-arrhythmic renal vasoconstriction in the dogCirculation.  58. 1978
    1977 Relation of renal hemodynamics to metabolism of angiotensin II by the canine kidney.Circulation Research.  41:283-287. 1977
    1977 Drug treatment of hypertension.Comprehensive Therapy.  3:34-46. 1977
    1977 Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy.Circulation Research.  40:428-434. 1977
    1977 Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro.American Journal of Physiology.  232:F319-F324. 1977
    1977 Treatment of hypertension by computer and physician-a prospective controlled study.Journal of chronic diseases.  30:81-92. 1977
    1977 Changing patterns of corticoid responses to ACTH during normal pregnancyClinical research.  25. 1977
    1977 Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitroFederation proceedings.  36. 1977
    1977 Sodium and mineralocorticoids in normal and abnormal pregnancy.Advances in Nephrology.  7:33-59. 1977
    1976 Altered angiotensin I conversion in pulmonary disease.Clinical science and molecular medicine.  51:537-543. 1976
    1976 Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive rat.Clinical science and molecular medicine. Supplement.  3:445s-459s. 1976
    1976 Inhibition of proximal tubular hydrolysis and reabsorption of bradykinin by peptides.American Journal of Physiology.  231:743-748. 1976
    1976 Oral-contraceptive-induced hypertension after adrenalectomy and hypophysectomy.Archives of Internal Medicine -New Series-.  136:1029-1031. 1976
    1976 Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule.American Journal of Physiology.  230:1420-1424. 1976
    1976 Theoretical approaches to estimation of plasma renin activity: a review and some original observations.Clinical Chemistry.  22:583-593. 1976
    1976 Managing heart disease in pregnancy.Rn -Montvale-.  39:ICU1-ICU8. 1976
    1976 Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive ratClinical science and molecular medicine.  51:455-459. 1976
    1976 Digitalis assay and its clinical application.Medical Clinics of North America.  60:193-207. 1976
    1976 Effects of renal hemodynamics on metabolism of angiotensin II (AII) by the dog kidneyFederation proceedings.  35. 1976
    1976 Inhibition of proximal tubular hydrolysis and reabsorption of angiotensin II by amino acidClinical research.  24. 1976
    1976 Inhibition of proximal tubular hydrolysis of bradykininFederation proceedings.  35. 1976
    1976 Mineralocorticoids in normal pregnancy.Perspectives in nephrology and hypertension.  5:189-201. 1976
    1976 Myocardial function and renin in the spontaneously hypertensive rat after central and peripheral sympathectomyClinical research.  24. 1976
    1976 Regulation of cortisol (F) secretion in pregnancyClinical research.  24. 1976
    1976 Structural requirements for the inhibition of renin release in vitro by the angiotensinsCirculation.  54. 1976
    1976 The renin-angiotensin system in mother and fetus at cesarean section: a preliminary communication.Perspectives in nephrology and hypertension.  5:287-292. 1976
    1976 Treatment of essential hypertension with a combination of hydrochlorothiazide, propranolol and methyldopaClinical research.  24. 1976
    1975 Plasma renin activity in hypertension.Comprehensive Therapy.  1:57-64. 1975
    1975 Prevention of hypertension in the SH rat: effects of differential central catecholamine depletion.Proceedings of the Society for Experimental Biology and Medicine.  150:748-754. 1975
    1975 Oral contraceptive pill hypertension.Journal of Reproductive Medicine.  15:201-208. 1975
    1975 Physician acceptance of computer recommended antihypertensive therapy.Computers and Biomedical Research.  8:492-502. 1975
    1975 Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity.Clinical science and molecular medicine.  49:139-147. 1975
    1975 Fate of labeled angiotensin II microinfused into individual nephrons in the rat.American Journal of Physiology.  228:747-751. 1975
    1975 Central catecholamine depletion and the prevention of hypertensionFederation proceedings.  34. 1975
    1975 Handling of small peptides by rat renal tubulesClinical research.  23. 1975
    1974 Effects of pH and enzyme inhibitors on apparent generation of angiotensin I in human plasma.Journal of Clinical Endocrinology and Metabolism.  39:965-968. 1974
    1974 The renin-angiotensin system (second of two parts).New England Journal of Medicine.  291:446-457. 1974
    1974 The Renin-Angiotensin SystemNew England Journal of Medicine.  291:389-401. 1974
    1974 The renin-angiotensin system (first of two parts).New England Journal of Medicine.  291:389-401. 1974
    1974 studies of plasma bradykininases using radiolabelled substrates.The Australian journal of experimental biology and medical science.  52:601-606. 1974
    1974 New polypeptide inhibitors of angiotensin conversionClinical research.  22. 1974
    1974 Structural requirements for substrates and inhibitors of angiotensin I-converting enzyme in vivo and vitro.Circulation Research.  34:19-26. 1974
    1973 Mechanism of renal handling of angiotensin II in the dog.Circulation Research.  33:500-507. 1973
    1973 Heart disease in pregnancy.Journal of Reproductive Medicine.  11:2-6. 1973
    1973 Substrate requirements for angiotensin I conversion in vivo and in vitro.Circulation Research.  32:415-423. 1973
    1973 Metabolism of angiotensin II (AII) by dog kidneyFederation proceedings.  32:3076. 1973
    1973 Polypeptide inhibitors of angiotensin converting enzymeClinical research.  21:441. 1973
    1972 Left-superior-vena-cava steal syndrome.New England Journal of Medicine.  286:303-304. 1972
    1971 Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog.Circulation Research.  29:682-690. 1971
    1971 Renin in differential diagnosis of hypertension.American Heart Journal.  82:568-570. 1971
    1970 In-vivo and in-vitro conversion of angiotensin I to angiotensin II in dog blood.Circulation Research.  26:591-599. 1970
    1970 Role of renin in acute postural homeostasis.Circulation.  41:89-95. 1970
    1966 Sex difference in fluid exchange during food deprivation in the rabbit.Endocrinology.  78:291-296. 1966
    Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.New England Journal of Medicine.  377:745-755.

    Book

    Year Title Altmetric
    2018 Impact of the SPRINT Trial on Hypertension Management..  Ed. 69.  2018
    2005 Preface 2005
    2005 Preface to the First Edition 2005
    1947 Hypertension..  Ed. 1.  1947

    Chapter

    Year Title Altmetric
    2018 Hypertension in women.  35-47. 2018
    2013 Hypertension and cardiovascular risk.  183-194. 2013
    2013 Pathogenesis of Hypertension.  12-26. 2013
    2012 Epidemiology of hypertension.  45-54. 2012
    2012 Initial evaluation and approach to the patient with hypertension.  463-473. 2012
    2012 Renin-angiotensin- aldosterone inhibitors in combination therapy.  53-64. 2012
    2010 Hypertensive Emergencies.  355-367. 2010
    2007 Fixed Low-Dose Antihypertensive Therapy.  1061-1073. 2007
    2007 Oral Contraceptives, Hormone Replacement Therapy, and Hypertension.  865-882. 2007
    2007 Pathophysiology of Hypertension.  25-46. 2007
    2007 Treatment of Hypertension in the Patient with Cardiovascular Disease.  625-646. 2007
    2005 Ischemic Heart Disease.  567-578. 2005
    2005 The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  340-351. 2005
    2005 The LIFE Study.  352-365. 2005
    2004 Hypertension and Sympathetic Nervous System Activity.  241-244. 2004

    Research Overview

  • Dr. Oparil's longstanding research interests include: lifestyle modification as an approach to prevent and treat cardiovascular diseases (CVDs), the aging heart and aging-associated predictors of chronic disease, pathophysiology and treatment of high blood pressure, the effects of aging on CVD in women and the relation between estrogen withdrawal and increase of CVD risk in postmenopausal women.

    Dr. Oparil has made many seminal contributions to vascular biology and hypertension research and has an impressive publication record of > 850 peer-reviewed articles on topics in clinical cardiology, atherosclerosis, heart failure, cardiovascular pathologies related to aging, vascular biology and hypertension and population science related to cardiovascular diseases.
  • Principal Investigator On

  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2022
  • Mechanisms of Hypertension and Cardiovascular Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by Bayer HealthCare 2015 - 2019
  • Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data  awarded by University of Minnesota 2017 - 2019
  • Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)  awarded by Brigham and Women's Hospital 2017 - 2019
  • Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Private Grant  awarded by ASTRAZENECA AB 2013 - 2016
  • A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus (EXSCEL)  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2010 - 2016
  • Mechanisms of Hypertension and Cardiovascular Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Bayer HealthCare 2016
  • TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy  awarded by Duke University 2009 - 2015
  • Private Grant  awarded by Bayer HealthCare 2014 - 2015
  • Private Grant  awarded by ARBOR PHARMACEUTICALS, LLC. 2014
  • O-GlyNAcylation: Novel Mechanism of Estrogen-Induced Vasoprotection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2013
  • Private Grant  awarded by AMARIN PHARMA, INC. 2013
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2013
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2013
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2011 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • Private Grant  awarded by VIVUS, INC. 2012
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2012
  • Private Grant  awarded by AMGEN, INC. 2010 - 2011
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2011
  • Integrated Regulation of Extracellular Matrix Expression in Cardiac Fibroblasts  awarded by American Heart Association 2010 - 2011
  • Mechanisms of Hypertension and Cardiovascular Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2006 - 2011
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2009 - 2011
  • Investigator On

  • Private Grant  awarded by IDORSIA PHARMACEUTICALS LTD 2018 - 2023
  • Private Grant  awarded by ROX MEDICAL INC. 2018 - 2023
  • Private Grant  awarded by VASCULAR DYNAMICS INC. 2018 - 2023
  • Private Grant  awarded by RECOR MEDICAL 2016 - 2023
  • Evaluating Novel Approaches for Estimating Awake and Sleep Blood Pressure  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2022
  • Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of Chronic Obstructive Pulmonary Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2020
  • Chronic Hypertension and Pregnancy-CHAP Clinical Coordinating Center  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2020
  • Collaboration to Improve Blood Pressure (BP) in the US Black Belt - Addressing the Triple Threat  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2020
  • Sustained Blood Pressure Control and Progression of Multimorbidity  awarded by Duke University 2017 - 2020
  • Neutrophil Dysregulation as a Driving Mechanism of Cardiovascular Disease in HIV-1-Infection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2020
  • Mechanisms of Refractory Hypertension  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2020
  • Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)  awarded by Brigham and Women's Hospital 2016 - 2020
  • Private Grant  awarded by GE HEALTHCARE 2018 - 2019
  • Private Grant  awarded by GE HEALTHCARE 2017 - 2019
  • The SPRINT· Alzheimer's, Seniors, and Kidney Study (SPRINT ASK)  awarded by WAKE FOREST UNIVERSITY 2017 - 2019
  • Cardiovascular Inflammation Reduction Trial (CIRT)  awarded by Brigham and Women's Hospital 2013 - 2019
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center  awarded by American Heart Association 2015 - 2019
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center - Mechanisms of Nocturnal Hypertension and Non-Dipping Blood Pressure - Project 2  awarded by American Heart Association 2015 - 2019
  • Targeted Cell Therapy for Acute Lung Injury  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by GEORGE CLINICAL 2017 - 2018
  • Private Grant  awarded by MEDTRONIC, INC. 2012 - 2018
  • Targeted Delivery of iPS-Endothelial Cells for the Repair of Cardiovascular Injury  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Project 2  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Visit-to-Visit Variability of Blood Pressure and CVD and Renal Outcomes  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2012 - 2016
  • Private Grant  awarded by TRIVASCULAR, INC. 2010 - 2015
  • Training Program in Cardiovascular Pathophysiology  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • Maintenance of Organ Function Following Injury  awarded by National Institute of General Medical Sciences/NIH/DHHS 2009 - 2014
  • Etiology of Sleep Apnea-Related Hyperaldosteronism  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2013
  • Cardiovascular Tissue and Cell Core  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2009 - 2013
  • Genetics of Hypertension Associated Treatment (GENHAT)  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2007 - 2012
  • Education And Training

  • Doctor of Medicine, Columbia University
  • Presbyterian Hospital, Internship 1966
  • Massachusetts General Hospital, Residency 1968
  • Presbyterian Hospital, Residency 1967
  • Massachusetts General Hospital, Postdoctoral Fellowship 1971
  • Full Name

  • Suzanne Oparil